{
    "questions": [
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/30146094"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30146094",
                    "offsetInBeginSection": 773,
                    "offsetInEndSection": 1038,
                    "text": "Nor is there sound evidence as to how subcutaneous non-FVIII/FIX replacement approaches (concizumab; emicizumab; fitusiran) or single intravenous injections of adeno-associated viral vectors (when employing gene therapy) will revolutionize adherence in haemophilia.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Concizumab is used for which diseases?",
            "type": "list",
            "id": "65cfad2d1930410b13000014",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24395523",
                "http://www.ncbi.nlm.nih.gov/pubmed/33688287",
                "http://www.ncbi.nlm.nih.gov/pubmed/31231783"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24395523",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 90,
                    "text": "The majority of stroke patients have clinically significant obstructive sleep apnea (OSA).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33688287",
                    "offsetInBeginSection": 1616,
                    "offsetInEndSection": 1746,
                    "text": "Patients in Cluster 2 had relatively lower risk of cardiovascular events and the benefits of OSA treatment requires further study.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31231783",
                    "offsetInBeginSection": 673,
                    "offsetInEndSection": 872,
                    "text": "Observational studies have shown an increased risk of ischemic stroke in patients with untreated OSA when compared with patients treated with CPAP; however, results are not statistically significant.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31231783",
                    "offsetInBeginSection": 873,
                    "offsetInEndSection": 987,
                    "text": "RCTs and meta-analyses have shown no significant ischemic stroke risk reduction in CPAP treated patients with OSA.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Do stroke patients have a lower risk of Obstructive Sleep Apnea?",
            "type": "yesno",
            "id": "65f7080fc4010b4d78000019",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/523668"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/523668",
                    "offsetInBeginSection": 442,
                    "offsetInEndSection": 520,
                    "text": "Approximately 75% of the infants, i.e. 15, died during the first week of life.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Should all babies diagnosed with spina bifida be operated within the first week of life?",
            "type": "yesno",
            "id": "65f859b2c4010b4d78000050",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/25841492",
                "http://www.ncbi.nlm.nih.gov/pubmed/27994940",
                "http://www.ncbi.nlm.nih.gov/pubmed/23255519",
                "http://www.ncbi.nlm.nih.gov/pubmed/22164924",
                "http://www.ncbi.nlm.nih.gov/pubmed/27247567",
                "http://www.ncbi.nlm.nih.gov/pubmed/19466295",
                "http://www.ncbi.nlm.nih.gov/pubmed/28103454"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25841492",
                    "offsetInBeginSection": 1092,
                    "offsetInEndSection": 1480,
                    "text": "Lynch syndrome also predisposes to a litany of extracolonic cancers, foremost of which is endometrial cancer, followed by cancer of the ovary, stomach, renal pelvis and ureter, small bowel, hepatobiliary tract, pancreas, glioblastoma multiforme in the Turcot's variant, and sebaceous skin tumors in the Muir-Torre variant and, more recently identified, cancers of the breast and prostate.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27994940",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 204,
                    "text": "Endometrial carcinoma (EC) is the most common extracolonic malignant neoplasm associated with Lynch syndrome (LS). LS is caused by autosomal dominant germline mutations in DNA mismatch repair (MMR) genes.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23255519",
                    "offsetInBeginSection": 267,
                    "offsetInEndSection": 376,
                    "text": "Carriers are at high-risk for developing colorectal carcinomas, as well as various extracolonic malignancies.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22164924",
                    "offsetInBeginSection": 380,
                    "offsetInEndSection": 716,
                    "text": "LS is caused by dominantly inherited mutations in the mismatch repair genes MLH1, MSH2, MSH6 or PMS2, and results in a very high lifetime risk (approximately 80%) for CRC and significantly increased risk for extracolonic tumors in regions such as the endometrium, ovary, urinary tract, lymphoma, stomach, pancreas small bowel and brain.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27247567",
                    "offsetInBeginSection": 138,
                    "offsetInEndSection": 282,
                    "text": "This syndrome is inherited in an autosomal dominant pattern and is characterized by early onset colorectal cancer (CRC) and extracolonic tumors.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19466295",
                    "offsetInBeginSection": 1013,
                    "offsetInEndSection": 1342,
                    "text": "Much progress has been made in understanding the molecular basis of Lynch Syndrome. Molecular characterization will be the most accurate way of defining Lynch syndrome and will provide predictive information of greater accuracy regarding the risks of colon and extracolonic cancer and enable optimal cancer surveillance regimens.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28103454",
                    "offsetInBeginSection": 315,
                    "offsetInEndSection": 373,
                    "text": "MSH2 having a higher association with extracolonic cancer.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28103454",
                    "offsetInBeginSection": 374,
                    "offsetInEndSection": 425,
                    "text": "MSH6 and PMS2 mutations have an atypical phenotype.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27247567",
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 137,
                    "text": "Lynch Syndrome (LS) is characterized by germline mutations in the DNA mismatch repair (MMR) genes MLH1, MSH2, MSH6, and PMS2.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What type of extracolonic tumors does the PMS2 germline mutation cause?",
            "type": "factoid",
            "id": "65f7736fc4010b4d78000024",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/20843489",
                "http://www.ncbi.nlm.nih.gov/pubmed/33070559",
                "http://www.ncbi.nlm.nih.gov/pubmed/29161609",
                "http://www.ncbi.nlm.nih.gov/pubmed/22289950",
                "http://www.ncbi.nlm.nih.gov/pubmed/32791859",
                "http://www.ncbi.nlm.nih.gov/pubmed/23276970",
                "http://www.ncbi.nlm.nih.gov/pubmed/19207714",
                "http://www.ncbi.nlm.nih.gov/pubmed/2300499",
                "http://www.ncbi.nlm.nih.gov/pubmed/23204938",
                "http://www.ncbi.nlm.nih.gov/pubmed/23720402"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20843489",
                    "offsetInBeginSection": 1063,
                    "offsetInEndSection": 1206,
                    "text": "The population attributable fractions (PAF) for excess weight were much higher for males (between 13.5% and 18.2%) than for females (2.3-4.6%).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33070559",
                    "offsetInBeginSection": 972,
                    "offsetInEndSection": 1114,
                    "text": "The PAFs of selected risk factors were 46.2% for colon and 42.4% for rectum among men, while 24.3% for colon and 18.9% for rectum among women.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29161609",
                    "offsetInBeginSection": 471,
                    "offsetInEndSection": 637,
                    "text": "An estimated 18,639 cancer cases diagnosed in France in 2015 were attributable to high BMI, corresponding to 5.3% of all cancer cases (6.7% in women and 4.1% in men).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22289950",
                    "offsetInBeginSection": 259,
                    "offsetInEndSection": 446,
                    "text": "The relative risk of colorectal cancer of obese patients is about 1.5 times higher than the normal-weight individuals, and obesity is also associated with premalignant colorectal adenoma.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32791859",
                    "offsetInBeginSection": 809,
                    "offsetInEndSection": 1015,
                    "text": "Compared with individuals with normal weight, overweight and obese young adults had a significantly higher risk of CRC (relative risks (RR):18%, 95% CI:1.08, 1.28; RR:32%, 95% CI: 1.11, 1.56, respectively).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23276970",
                    "offsetInBeginSection": 340,
                    "offsetInEndSection": 484,
                    "text": "The relative risk associated with obesity is higher for cancer of the colon than for cancer of the rectum and it is higher in men than in women.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19207714",
                    "offsetInBeginSection": 815,
                    "offsetInEndSection": 976,
                    "text": "Higher BMI was associated with colon (RR 1.24, 95% CIs: 1.20-1.28) and rectal (1.09, 1.05-1.14) cancers in men, and with colon cancer (1.09, 1.04-1.12) in women.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2300499",
                    "offsetInBeginSection": 407,
                    "offsetInEndSection": 556,
                    "text": "There was a statistically significant increase in the risk of rectal cancer but not of colon cancer in overweight and obese males but not in females.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23204938",
                    "offsetInBeginSection": 327,
                    "offsetInEndSection": 486,
                    "text": "There is a weaker association between obesity and colon cancer in women than in men, and no appreciable association between obesity and rectal cancer in women.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23720402",
                    "offsetInBeginSection": 958,
                    "offsetInEndSection": 1024,
                    "text": "In women, anthropometric variables were unrelated to colon cancer.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What proportion of risk is attributable to obesity in colorectal cancer women development?",
            "type": "factoid",
            "id": "65f7728fc4010b4d78000021",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/35915689",
                "http://www.ncbi.nlm.nih.gov/pubmed/36405923",
                "http://www.ncbi.nlm.nih.gov/pubmed/30949077",
                "http://www.ncbi.nlm.nih.gov/pubmed/24648791",
                "http://www.ncbi.nlm.nih.gov/pubmed/24740469",
                "http://www.ncbi.nlm.nih.gov/pubmed/26579955",
                "http://www.ncbi.nlm.nih.gov/pubmed/26371762",
                "http://www.ncbi.nlm.nih.gov/pubmed/34708874",
                "http://www.ncbi.nlm.nih.gov/pubmed/31437480",
                "http://www.ncbi.nlm.nih.gov/pubmed/34465250"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35915689",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 260,
                    "text": "The Food and Drug Administration (FDA) granted breakthrough therapy status to 3,4-methylenedioxymethamphetamine-assisted therapy (MDMA-AT) in 2017 due to preliminary evidence supporting its efficacy and safety in treating post-traumatic stress disorder (PTSD).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35915689",
                    "offsetInBeginSection": 261,
                    "offsetInEndSection": 495,
                    "text": "A series of six phase-II clinical trials studying MDMA-AT for treatment-resistant PTSD found that 54% of MDMA-AT full-dose participants no longer met the diagnosis of PTSD after two MDMA sessions, compared to 23% in the control group.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35915689",
                    "offsetInBeginSection": 496,
                    "offsetInEndSection": 596,
                    "text": "In the first phase-III clinical trial, 67% no longer met the criteria for PTSD after three sessions.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35915689",
                    "offsetInBeginSection": 597,
                    "offsetInEndSection": 697,
                    "text": "The effects are durable, with 67% no longer diagnosable after one year and 74% at nearly four years.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35915689",
                    "offsetInBeginSection": 698,
                    "offsetInEndSection": 767,
                    "text": "The MDMA-AT is being fast-tracked for potential FDA approval by 2023.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36405923",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 181,
                    "text": "Increasing evidence demonstrates 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy (MDMA-AT) may be a safe and effective treatment for post-traumatic stress disorder (PTSD).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36405923",
                    "offsetInBeginSection": 795,
                    "offsetInEndSection": 1001,
                    "text": "Findings demonstrate a high prevalence of chronic pain in this sample of people with severe PTSD and that chronic pain scores among medium and high pain subgroups were significantly lower following MDMA-AT.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30949077",
                    "offsetInBeginSection": 187,
                    "offsetInEndSection": 324,
                    "text": "Most clinical MDMA research in patients to date has focused on MDMA-assisted psychotherapy to treat posttraumatic stress disorder (PTSD).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30949077",
                    "offsetInBeginSection": 613,
                    "offsetInEndSection": 755,
                    "text": "MDMA therapy for PTSD is now entering the final Phase 3 stage of drug development, with a target set for licensing by the FDA and EMA in 2021.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24648791",
                    "offsetInBeginSection": 2011,
                    "offsetInEndSection": 2242,
                    "text": "Finally, even though MDMA is listed as a Schedule I compound by the Drug Enforcement Agency, MDMA-assisted psychotherapy for patients with chronic, treatment-resistant posttraumatic stress disorder is currently under investigation.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Has MDMA(ecstasy) been successfully used to treat PTSD disorder?",
            "type": "yesno",
            "id": "65f490fac4010b4d78000010",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/3584810",
                "http://www.ncbi.nlm.nih.gov/pubmed/10711989",
                "http://www.ncbi.nlm.nih.gov/pubmed/28303574",
                "http://www.ncbi.nlm.nih.gov/pubmed/30837270",
                "http://www.ncbi.nlm.nih.gov/pubmed/27980005",
                "http://www.ncbi.nlm.nih.gov/pubmed/8784803",
                "http://www.ncbi.nlm.nih.gov/pubmed/17296297",
                "http://www.ncbi.nlm.nih.gov/pubmed/9392017",
                "http://www.ncbi.nlm.nih.gov/pubmed/9296168",
                "http://www.ncbi.nlm.nih.gov/pubmed/9392015"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3584810",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 120,
                    "text": "Oculopharyngeal muscular dystrophy (OPMD) is a rare progressive disease characterized by bilateral ptosis and dysphagia.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10711989",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 115,
                    "text": "Autosomal dominant oculopharyngeal muscular dystrophy (OPMD) is an adult-onset disease with worldwide distribution.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10711989",
                    "offsetInBeginSection": 116,
                    "offsetInEndSection": 236,
                    "text": "It usually presents in the fifth or sixth decades with progressive dysphagia, eyelid ptosis, and proximal limb weakness.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10711989",
                    "offsetInBeginSection": 237,
                    "offsetInEndSection": 334,
                    "text": "Unique intranuclear filament inclusions in skeletal muscle fibers are its morphological hallmark.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28303574",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 126,
                    "text": "Mutations in the gene encoding poly(A)-binding protein nuclear 1 (PABPN1) result in oculopharyngeal muscular dystrophy (OPMD).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28303574",
                    "offsetInBeginSection": 202,
                    "offsetInEndSection": 331,
                    "text": "Oculopharyngeal muscular dystrophy (OPMD) is linked to mutations in the gene encoding poly(A)-binding protein nuclear 1 (PABPN1).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28303574",
                    "offsetInBeginSection": 332,
                    "offsetInEndSection": 419,
                    "text": "OPMD mutations consist of an expansion of a tract that contains 10 alanines (to 12-17).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28303574",
                    "offsetInBeginSection": 420,
                    "offsetInEndSection": 528,
                    "text": "This disease courses with muscle weakness that begins in adulthood, but the underlying mechanism is unclear.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30837270",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 127,
                    "text": "Oculopharyngeal muscular dystrophy (OPMD) is a late-onset, primarily autosomal dominant disease caused by a short GCN expansion",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27980005",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 156,
                    "text": "Oculopharyngeal muscular dystrophy (OPMD) is an autosomal-dominant, adult-onset disorder defined by blepharoptosis, dysphagia, and proximal muscle weakness.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is Oculopharyngeal Muscular Dystrophy (OPMD)?",
            "type": "summary",
            "id": "6446884b57b1c7a31500006f",
            "ideal_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/31401950",
                "http://www.ncbi.nlm.nih.gov/pubmed/29518153",
                "http://www.ncbi.nlm.nih.gov/pubmed/31401965",
                "http://www.ncbi.nlm.nih.gov/pubmed/31401955",
                "http://www.ncbi.nlm.nih.gov/pubmed/37007505",
                "http://www.ncbi.nlm.nih.gov/pubmed/19281304",
                "http://www.ncbi.nlm.nih.gov/pubmed/33195512",
                "http://www.ncbi.nlm.nih.gov/pubmed/21976568",
                "http://www.ncbi.nlm.nih.gov/pubmed/34224652",
                "http://www.ncbi.nlm.nih.gov/pubmed/31463770"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31401950",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 147,
                    "text": "Predicting pathogen spillover requires counting spillover events and aligning such counts with process-related covariates for each spillover event.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31401950",
                    "offsetInBeginSection": 292,
                    "offsetInEndSection": 529,
                    "text": "We illustrate how the pathways to pathogen spillover can be represented as a directed graph connecting reservoir hosts and recipient hosts and the number of spillover events modelled as a percolation of infectious units along that graph.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29518153",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 145,
                    "text": "HIV-1 arose as the result of spillover of simian immunodeficiency viruses (SIVs) from great apes in Africa, namely from chimpanzees and gorillas.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29518153",
                    "offsetInBeginSection": 251,
                    "offsetInEndSection": 337,
                    "text": "During spillover events, SIV is thought to require adaptation to the new host species.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31401965",
                    "offsetInBeginSection": 167,
                    "offsetInEndSection": 271,
                    "text": "One approach to estimating spillover is to directly correlate observed spillover events with covariates.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31401965",
                    "offsetInBeginSection": 272,
                    "offsetInEndSection": 448,
                    "text": "An alternative is to mechanistically combine information on host density, distribution and pathogen prevalence to predict where and when spillover events are expected to occur.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31401965",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 166,
                    "text": "For pathogens known to transmit across host species, strategic investment in disease control requires knowledge about where and when spillover transmission is likely.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31401955",
                    "offsetInBeginSection": 610,
                    "offsetInEndSection": 766,
                    "text": "Here, we review the dose-response literature and discuss the unique role dose-response models have to play in understanding and predicting spillover events.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31401955",
                    "offsetInBeginSection": 161,
                    "offsetInEndSection": 361,
                    "text": "Understanding the relationship between dose and disease is particularly important in the context of spillover, where nonlinearities in the dose-response could determine the likelihood of transmission.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37007505",
                    "offsetInBeginSection": 438,
                    "offsetInEndSection": 670,
                    "text": "Here we aim to provide a synthetic explanation by arguing that domestication, horizontal gene transfer even between superkingdoms as well as gradual exchange of microbiome (microbiome succession) are essential in the whole scenario.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is a spillover event?",
            "type": "summary",
            "id": "65f843cbc4010b4d78000042",
            "ideal_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/17217858",
                "http://www.ncbi.nlm.nih.gov/pubmed/19021551",
                "http://www.ncbi.nlm.nih.gov/pubmed/17567779",
                "http://www.ncbi.nlm.nih.gov/pubmed/23500067",
                "http://www.ncbi.nlm.nih.gov/pubmed/35607917",
                "http://www.ncbi.nlm.nih.gov/pubmed/10382910",
                "http://www.ncbi.nlm.nih.gov/pubmed/16550925",
                "http://www.ncbi.nlm.nih.gov/pubmed/37309342",
                "http://www.ncbi.nlm.nih.gov/pubmed/15967842",
                "http://www.ncbi.nlm.nih.gov/pubmed/12138994"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17217858",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 89,
                    "text": "Emery-Dreifuss muscular dystrophy (EDMD) is inherited in an X-linked or autosomal manner.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17217858",
                    "offsetInBeginSection": 90,
                    "offsetInEndSection": 222,
                    "text": "X-linked EDMD is caused by mutations in EMD, which encodes an integral protein of the nuclear envelope inner membrane called emerin.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17217858",
                    "offsetInBeginSection": 223,
                    "offsetInEndSection": 389,
                    "text": "Autosomally inherited EDMD is caused by mutations in LMNA, which encodes A-type nuclear lamins, intermediate filament proteins associated with inner nuclear membrane.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19021551",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 169,
                    "text": "EDMD (Emery-Dreifuss muscular dystrophy) is caused by mutations in either the gene encoding for lamin A/C (LMNA) located at 1q21.2-q21.3 or emerin (EMD) located at Xq28.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19021551",
                    "offsetInBeginSection": 170,
                    "offsetInEndSection": 302,
                    "text": "Autosomal dominant EDMD caused by LMNA mutations is more common than the X-linked form and often more severe, with an earlier onset.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17567779",
                    "offsetInBeginSection": 233,
                    "offsetInEndSection": 359,
                    "text": "Mutations in EMD, encoding emerin, and LMNA, encoding A-type lamins, respectively, cause X-linked and autosomal dominant EDMD.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23500067",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 160,
                    "text": "Emery Dreifuss muscular dystrophy (EDMD) is a hereditary muscular disorder, characterized by contractures, progressive muscular wasting and cardiac involvement.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23500067",
                    "offsetInBeginSection": 161,
                    "offsetInEndSection": 255,
                    "text": "The majority of EDMD patients harbor mutations in the lamin A/C (LMNA) and emerin (STA) genes.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23500067",
                    "offsetInBeginSection": 256,
                    "offsetInEndSection": 385,
                    "text": "Emerging data implicate mutations in FHL1 (four and a half LIM protein 1) gene, located in chromosome Xq26, in EDMD pathogenesis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35607917",
                    "offsetInBeginSection": 199,
                    "offsetInEndSection": 284,
                    "text": "Pathogenic variants in FHL1 can cause a rare X-linked recessive form of EDMD, type 6.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "How can Emery-Dreifuss Muscular Dystrophy (EDMD) be inherited?",
            "type": "list",
            "id": "64467f8657b1c7a31500006d",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/16394182",
                "http://www.ncbi.nlm.nih.gov/pubmed/16173059",
                "http://www.ncbi.nlm.nih.gov/pubmed/19854188",
                "http://www.ncbi.nlm.nih.gov/pubmed/27864110",
                "http://www.ncbi.nlm.nih.gov/pubmed/14654105",
                "http://www.ncbi.nlm.nih.gov/pubmed/29438782",
                "http://www.ncbi.nlm.nih.gov/pubmed/21524089",
                "http://www.ncbi.nlm.nih.gov/pubmed/35696943",
                "http://www.ncbi.nlm.nih.gov/pubmed/36050717",
                "http://www.ncbi.nlm.nih.gov/pubmed/24384226"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16394182",
                    "offsetInBeginSection": 244,
                    "offsetInEndSection": 565,
                    "text": "Here, we show that arvanil inhibits early events in T-cell receptor (TCR)-mediated T-cell activation, such as calcium mobilization and nuclear factor of activated T-cell activation, and in late events in TCR-mediated activation, such as interleukin (IL)-2 gene transcription, IL-2R expression, and cell-cycle progression.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16173059",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 181,
                    "text": "Activation of the capsaicin receptor (VR1 or TRPV1) in bronchial epithelial cells by capsaicinoids and other vanilloids promotes pro-inflammatory cytokine production and cell death.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16173059",
                    "offsetInBeginSection": 397,
                    "offsetInEndSection": 623,
                    "text": "TRPV1 antagonists and reduction of calcium concentrations in treatment solutions attenuated calcium flux, induction of interleukin-6 and 8 gene expression, and IL-6 secretion by cells treated with capsaicin or resiniferatoxin.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19854188",
                    "offsetInBeginSection": 655,
                    "offsetInEndSection": 779,
                    "text": "An unidentified mechanism whereby evodiamine inhibits adipogenesis via the EGFR-PKCalpha-ERK signaling pathway was revealed.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27864110",
                    "offsetInBeginSection": 194,
                    "offsetInEndSection": 461,
                    "text": "The goal of the present study was to evaluate the antinociceptive effect of the crude extract (Crd) and dichloromethane fraction (Dcm) of A. crucigerum seeds, and investigate the involvement of transient receptor potential vanilloid 1 (TRPV1) receptor in this effect.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14654105",
                    "offsetInBeginSection": 476,
                    "offsetInEndSection": 615,
                    "text": "SB-366791 is a novel, potent, and selective, cinnamide TRPV1 antagonist isolated via high-throughput screening of a large chemical library.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14654105",
                    "offsetInBeginSection": 647,
                    "offsetInEndSection": 772,
                    "text": "SB-366791 produced a concentration-dependent inhibition of the response to capsaicin with an apparent pK(b) of 7.74 +/- 0.08.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14654105",
                    "offsetInBeginSection": 890,
                    "offsetInEndSection": 1052,
                    "text": "SB-366791 was demonstrated to be an effective antagonist of hTRPV1 when activated by different modalities, such as capsaicin, acid or noxious heat (50 degrees C).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29438782",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 240,
                    "text": "Semicarbazide-sensitive amine oxidase (SSAO) produces tissue irritants by deamination of primary amines, which activate transient receptor potential ankyrin 1 (TRPA1) and vanilloid 1 (TRPV1) receptors expressed predominantly on nociceptors.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29438782",
                    "offsetInBeginSection": 294,
                    "offsetInEndSection": 454,
                    "text": "we studied the effects and mechanisms of action of our novel SSAO inhibitor and dual TRPA1/TRPV1 antagonist multi-target drug SZV 1287 in different pain models.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is the mechanisms of action of Dersimelagon?",
            "type": "summary",
            "id": "65d144731930410b13000040",
            "ideal_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/25400349",
                "http://www.ncbi.nlm.nih.gov/pubmed/19892633",
                "http://www.ncbi.nlm.nih.gov/pubmed/36381886",
                "http://www.ncbi.nlm.nih.gov/pubmed/31190658",
                "http://www.ncbi.nlm.nih.gov/pubmed/19198722",
                "http://www.ncbi.nlm.nih.gov/pubmed/20196403",
                "http://www.ncbi.nlm.nih.gov/pubmed/3145286",
                "http://www.ncbi.nlm.nih.gov/pubmed/15194961",
                "http://www.ncbi.nlm.nih.gov/pubmed/16454531",
                "http://www.ncbi.nlm.nih.gov/pubmed/28953852"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25400349",
                    "offsetInBeginSection": 701,
                    "offsetInEndSection": 812,
                    "text": "Therefore, we strongly recommend avoidance of valproic acid and supplementation of folic acid during pregnancy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19892633",
                    "offsetInBeginSection": 238,
                    "offsetInEndSection": 500,
                    "text": "Women of childbearing age taking valproate should be warned of its teratogenicity and advised to plan pregnancies, take a higher dose of folate, discuss reducing the dose of valproate or changing the medication with their physician, and have antenatal screening.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36381886",
                    "offsetInBeginSection": 171,
                    "offsetInEndSection": 254,
                    "text": "This review debates whether the usage of valproic acid is appropriate in pregnancy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36381886",
                    "offsetInBeginSection": 563,
                    "offsetInEndSection": 844,
                    "text": "It also includes the importance of awareness among middle-aged women with mental illness regarding the teratogenic effects of sodium valproate use and the relevance of discussion by physicians with patients regarding the usage of this drug despite being aware of the complications.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19892633",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 109,
                    "text": "Sodium valproate is a teratogen responsible for a wide range of abnormalities, including neural tube defects.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31190658",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 177,
                    "text": "Sodium valproate and related preparations have recently undergone regulatory review following concern about effects on the unborn child and doctors' failure to communicate risk.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31190658",
                    "offsetInBeginSection": 492,
                    "offsetInEndSection": 617,
                    "text": "Valproate may be useful in a small number of patients with bipolar disorder but current prescribing patterns are unjustified.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19198722",
                    "offsetInBeginSection": 810,
                    "offsetInEndSection": 958,
                    "text": "Therefore, we recommend that valproic acid must be avoided during pregnancy, as new generation of anticonvulsant drugs have emerged into the market.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20196403",
                    "offsetInBeginSection": 818,
                    "offsetInEndSection": 1103,
                    "text": "Based on these patients, we aimed to add further evidence in the literature indicating that the use of sodium valproate alone and in combination with other anti-epileptic drugs throughout pregnancy can increase the risk of serious fetal congenital malformations depending on the doses.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3145286",
                    "offsetInBeginSection": 933,
                    "offsetInEndSection": 1057,
                    "text": "Sodium valproate was found to induce developmental toxicity in the CD-1 mouse fetus at human therapeutic drug plasma levels.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Can valproate be used during pregnancy?",
            "type": "yesno",
            "id": "65d12b451930410b13000031",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [],
            "snippets": [],
            "body": "Is measles immunisation the best public health approach to reduce incidence of measles worldwide?",
            "type": "yesno",
            "id": "65f84d20c4010b4d7800004a",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [],
            "snippets": [],
            "body": "What are active ingredients of Trikafta?",
            "type": "list",
            "id": "65d137871930410b1300003e",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/33130193",
                "http://www.ncbi.nlm.nih.gov/pubmed/34569969",
                "http://www.ncbi.nlm.nih.gov/pubmed/30171533"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33130193",
                    "offsetInBeginSection": 742,
                    "offsetInEndSection": 921,
                    "text": "Additionally, drug therapies including eteplirsen (EXONDYS 51), golodirsen (VYONDYS 53TM), and viltolarsen (VILTEPSO) have been approved by the FDA to treat specific types of DMD.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34569969",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 198,
                    "text": "Recently, the Food and Drug Administration granted accelerated approvals for four exon skipping therapies -Eteplirsen, Golodirsen, Viltolarsen, and Casimersen -for Duchenne Muscular Dystrophy (DMD).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30171533",
                    "offsetInBeginSection": 650,
                    "offsetInEndSection": 845,
                    "text": "Eteplirsen (brand name Exondys 51), is the first approved antisense therapy for DMD in the USA, and provides a treatment option for ~14% of all DMD patients, who are amenable to exon 51 skipping.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30171533",
                    "offsetInBeginSection": 846,
                    "offsetInEndSection": 1038,
                    "text": "Eteplirsen is granted accelerated approval and marketing authorization by the US Food and Drug Administration (FDA), on the condition that additional postapproval trials show clinical benefit.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What type of DMD can golodirsen be used for?",
            "type": "factoid",
            "id": "64179034690f196b5100002b",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/32627883",
                "http://www.ncbi.nlm.nih.gov/pubmed/33593392",
                "http://www.ncbi.nlm.nih.gov/pubmed/34402529",
                "http://www.ncbi.nlm.nih.gov/pubmed/36946696",
                "http://www.ncbi.nlm.nih.gov/pubmed/36156476",
                "http://www.ncbi.nlm.nih.gov/pubmed/37451841",
                "http://www.ncbi.nlm.nih.gov/pubmed/36089643",
                "http://www.ncbi.nlm.nih.gov/pubmed/31792356"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32627883",
                    "offsetInBeginSection": 982,
                    "offsetInEndSection": 1093,
                    "text": "For the first time, the prevalence of NTRK gene fusion was observed to be around 7% in the MSI-high CRC cohort.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33593392",
                    "offsetInBeginSection": 629,
                    "offsetInEndSection": 811,
                    "text": "The profiles in six CRC cohorts showed that NTRKs gene promoter was more frequently methylated in CRC compared to normal mucosa, which was associated with suppressed gene expression.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34402529",
                    "offsetInBeginSection": 945,
                    "offsetInEndSection": 1135,
                    "text": "TRK positivity was observed in 11 of 58 (19%) MLH1-methylated MSI-high CRCs, 4 of 23 (17%) sessile serrated lesions with dysplasia (SSLDs), and 5 of 132 (4%) sessile serrated lesions (SSLs).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36946696",
                    "offsetInBeginSection": 476,
                    "offsetInEndSection": 642,
                    "text": "The prevalence of NTRK fusion (tissue NGS) in the pan-cancer population was 0.18%, with 46 unique NTRK-fusion partner pairs, of which 33 were not previously reported.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36156476",
                    "offsetInBeginSection": 1346,
                    "offsetInEndSection": 1512,
                    "text": "Targeted therapies are recommended for advanced or mCRC patients with KRAS/NRAS/BRAF mutated or wild-type tumors, HER2-amplified tumors, and NTRK gene fusion-positive",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37451841",
                    "offsetInBeginSection": 943,
                    "offsetInEndSection": 1072,
                    "text": "Our results indicate that NTRK gene alterations are not enriched in GC with dMMR but are specifically enriched in cases of GAHED.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36089643",
                    "offsetInBeginSection": 1595,
                    "offsetInEndSection": 1748,
                    "text": "Solid tumor types reported in at least 10% of the study cohort were lung (24.5%), cholangiocarcinoma (13.6%), pancreatic (10.9%), and colorectal (10.0%).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31792356",
                    "offsetInBeginSection": 646,
                    "offsetInEndSection": 696,
                    "text": "Pan-Trk IHC was positive in 0.2% of CRCs (9/4569).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What proportion of alteration in NTRK genes are attributable to colorectal cancer?",
            "type": "factoid",
            "id": "65f77397c4010b4d78000025",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/30730633",
                "http://www.ncbi.nlm.nih.gov/pubmed/34022424",
                "http://www.ncbi.nlm.nih.gov/pubmed/15022777",
                "http://www.ncbi.nlm.nih.gov/pubmed/11064756",
                "http://www.ncbi.nlm.nih.gov/pubmed/33465125",
                "http://www.ncbi.nlm.nih.gov/pubmed/26981125",
                "http://www.ncbi.nlm.nih.gov/pubmed/22797995",
                "http://www.ncbi.nlm.nih.gov/pubmed/33995348",
                "http://www.ncbi.nlm.nih.gov/pubmed/9186382",
                "http://www.ncbi.nlm.nih.gov/pubmed/28407772"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30730633",
                    "offsetInBeginSection": 1217,
                    "offsetInEndSection": 1289,
                    "text": "The incidence of severe malaria was only reduced in the older age group.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34022424",
                    "offsetInBeginSection": 1338,
                    "offsetInEndSection": 1505,
                    "text": "These findings suggest that female infants and young children with clinical malaria might be at a greater risk of morbidity characterized by higher serum HMGB1 levels.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34022424",
                    "offsetInBeginSection": 526,
                    "offsetInEndSection": 816,
                    "text": "Here, we show significant sex differences in serum concentrations of HMGB1, a non-histone chromatin-associated protein, and numbers of pigmented monocytes, which are both markers of severe malaria, in infants and young children <5 years old from a malaria endemic region in Northern Uganda.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15022777",
                    "offsetInBeginSection": 260,
                    "offsetInEndSection": 385,
                    "text": "Children are at high risk for severe forms, since malarial immunity is not yet acquired and symptoms are rapidly progressive.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11064756",
                    "offsetInBeginSection": 1167,
                    "offsetInEndSection": 1398,
                    "text": "Although the clinical characteristics and responses to oral therapy of children with and without HP are therefore very similar, young children with HP appear to have an increased risk of developing other features of severe malaria.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11064756",
                    "offsetInBeginSection": 885,
                    "offsetInEndSection": 1094,
                    "text": "Three children in the HP group, all aged < 3 years, progressed to cerebral malaria within 8 h of presentation, and another HP child presented with isolated trunkal ataxia, indicative of cerebellar involvement.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30730633",
                    "offsetInBeginSection": 889,
                    "offsetInEndSection": 1042,
                    "text": "In these trials, three injections of the malaria vaccine one month apart did not reduce overall mortality or malaria mortality in low-mortality settings.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33465125",
                    "offsetInBeginSection": 109,
                    "offsetInEndSection": 174,
                    "text": "Young children and pregnant women are hit hardest by the disease.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26981125",
                    "offsetInBeginSection": 1168,
                    "offsetInEndSection": 1290,
                    "text": "Participants with complicated falciparum malaria were generally anaemic and younger than those with uncomplicated disease.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22797995",
                    "offsetInBeginSection": 223,
                    "offsetInEndSection": 415,
                    "text": "The dilemma is how to move forward with interventions to prevent iron deficiency and its consequences in young children, using strategies that minimize risks of malaria and related infections.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Are only babies and young children at risk of severe malaria in endemic areas?",
            "type": "yesno",
            "id": "65f83281c4010b4d78000040",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/25488145",
                "http://www.ncbi.nlm.nih.gov/pubmed/25155761",
                "http://www.ncbi.nlm.nih.gov/pubmed/19703259",
                "http://www.ncbi.nlm.nih.gov/pubmed/23577027",
                "http://www.ncbi.nlm.nih.gov/pubmed/28984495",
                "http://www.ncbi.nlm.nih.gov/pubmed/18296350",
                "http://www.ncbi.nlm.nih.gov/pubmed/36836621",
                "http://www.ncbi.nlm.nih.gov/pubmed/23579425",
                "http://www.ncbi.nlm.nih.gov/pubmed/20122631",
                "http://www.ncbi.nlm.nih.gov/pubmed/31233770"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25488145",
                    "offsetInBeginSection": 1641,
                    "offsetInEndSection": 1838,
                    "text": "Overall, high-DII diets are associated with increased risk of CRC, particularly for colon cancer, suggesting that dietary-mediated inflammation plays an important role in colorectal carcinogenesis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25155761",
                    "offsetInBeginSection": 1510,
                    "offsetInEndSection": 1661,
                    "text": "These results indicate that a proinflammatory diet, as indicated by higher DII scores, was associated with higher risk of developing colorectal cancer.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25155761",
                    "offsetInBeginSection": 1662,
                    "offsetInEndSection": 1740,
                    "text": "Proinflammatory diets are associated with increased risk of colorectal cancer.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19703259",
                    "offsetInBeginSection": 609,
                    "offsetInEndSection": 923,
                    "text": "The literature indicates that fecal water activity markers are affected by specific dietary components linked with CRC risk: red meat, saturated fats, bile acids, and fatty acids are associated with an increase in fecal water toxicity, while the converse appears to be true for calcium, probiotics, and prebiotics.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23577027",
                    "offsetInBeginSection": 715,
                    "offsetInEndSection": 928,
                    "text": "For alcohol, there seems to be a stronger association with rectal cancer than with colon cancer, and for meat a somewhat stronger association with distal colon and rectal cancer, relative to proximal colon cancer.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23577027",
                    "offsetInBeginSection": 929,
                    "offsetInEndSection": 1026,
                    "text": "For fiber, milk, and calcium, there were only minor differences in relative risk across subsites.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28984495",
                    "offsetInBeginSection": 180,
                    "offsetInEndSection": 304,
                    "text": "We reviewed the evidences regarding the effect of different dietary FAs on human CRC cell lines proliferation and apoptosis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28984495",
                    "offsetInBeginSection": 305,
                    "offsetInEndSection": 657,
                    "text": "Altogether, the results obtained from in vitro studies show that monounsaturated FAs lack evidence regarding both proliferation and apoptosis, whereas there is a consensus about the anti-proliferative and pro-apoptotic effects, involving different intracellular targets, of n-3 polyunsaturated FAs, while n-6 series show a similar effect or no effects.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18296350",
                    "offsetInBeginSection": 291,
                    "offsetInEndSection": 437,
                    "text": "Evidence suggests that the components of the insulin-like growth factor (IGF) system may be appropriate targets for cancer prevention and therapy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18296350",
                    "offsetInBeginSection": 438,
                    "offsetInEndSection": 549,
                    "text": "A positive correlation was found between dietary and lifestyle, plasma IGF-I, and colon cancer incidence rates.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Which dietary compounds are associated with colorectal cancer incidence?",
            "type": "list",
            "id": "65f7725ec4010b4d78000020",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/37403937",
                "http://www.ncbi.nlm.nih.gov/pubmed/36720180"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37403937",
                    "offsetInBeginSection": 58,
                    "offsetInEndSection": 299,
                    "text": "This study tested the anti-cancer chimeric antigen receptor-T cell (CAR-T) therapy ciltacabtagene autoleucel, abbreviated as cilta-cel, in people with multiple myeloma, a cancer that affects a specific type of blood cell called plasma cells.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36720180",
                    "offsetInBeginSection": 118,
                    "offsetInEndSection": 360,
                    "text": "Ciltacabtagene autoleucel (cilta-cel), a second-generation CAR-T cell with double B cell maturation antigen (BCMA) targeting binding domains, showed an 88% overall response rate (ORR) in patients with relapsed/refractory multiple myeloma (MM)",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Cilta-cel was developed for treatment of which disease?",
            "type": "factoid",
            "id": "65cfd4b21930410b13000020",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [],
            "snippets": [],
            "body": "Which oncogene somatic mutations are associated to in situ carcinoma evolution from colonic polyp adenomas?",
            "type": "list",
            "id": "65f772d3c4010b4d78000022",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/36913180",
                "http://www.ncbi.nlm.nih.gov/pubmed/37036140",
                "http://www.ncbi.nlm.nih.gov/pubmed/35505771",
                "http://www.ncbi.nlm.nih.gov/pubmed/37226522",
                "http://www.ncbi.nlm.nih.gov/pubmed/36936239",
                "http://www.ncbi.nlm.nih.gov/pubmed/28523588",
                "http://www.ncbi.nlm.nih.gov/pubmed/33207299",
                "http://www.ncbi.nlm.nih.gov/pubmed/32440190",
                "http://www.ncbi.nlm.nih.gov/pubmed/32873116",
                "http://www.ncbi.nlm.nih.gov/pubmed/31227590"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36913180",
                    "offsetInBeginSection": 340,
                    "offsetInEndSection": 583,
                    "text": "Tofacitinib, a non-selective small molecule JAK inhibitor, and upadacitinib and filgotinib, which are selective JAK-1 inhibitors, have been approved by the US Food and Drug Administration (FDA) for moderate-to-severe active ulcerative colitis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37036140",
                    "offsetInBeginSection": 419,
                    "offsetInEndSection": 596,
                    "text": "Currently, in Japan, three Janus kinase inhibitors, namely tofacitinib, filgotinib, and upadacitinib, are available for the treatment of patients with active ulcerative colitis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35505771",
                    "offsetInBeginSection": 250,
                    "offsetInEndSection": 447,
                    "text": "Tofacitinib was the first pan-Janus kinase (Jak) inhibitor approved for the treatment of IBD, targeting the 4 isoforms of cytokine-associated Jaks (Jak1, Jak2, Jak3, and tyrosine-protein kinase 2).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37226522",
                    "offsetInBeginSection": 575,
                    "offsetInEndSection": 793,
                    "text": "Janus Kinase inhibitors are considered among the 'advanced therapies' for IBD and are approved for the treatment of moderate to severe ulcerative colitis in adults with pending approvals for Crohn's disease in the U.S.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36936239",
                    "offsetInBeginSection": 1071,
                    "offsetInEndSection": 1231,
                    "text": "Although there are currently no approved JAK inhibitors for Crohn's disease, upadacitinib and filgotinib have shown increased remission rates in these patients.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28523588",
                    "offsetInBeginSection": 952,
                    "offsetInEndSection": 1181,
                    "text": "Currently developed to treat ulcerative colitis and Crohn's disease, tofacitinib (in a phase III study) and filgotinib (in a phase II study), respectively, are the JAK inhibitors in the most advanced stage of development for IBD.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33207299",
                    "offsetInBeginSection": 226,
                    "offsetInEndSection": 641,
                    "text": "Tofacitinib is the first compound of a promising class of new small molecules approved for the treatment of IBD. This pan-Janus kinase (JAK) inhibitor (JAKi) targets the four isoforms of cytokine associated JAKs (JAK1, JAK2, JAK3 and TYK2). Next generations JAKi with marked selectivity for specific JAK isoforms or gut-restricted effect are in development, with promising results in phase I and II clinical trials.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32440190",
                    "offsetInBeginSection": 1066,
                    "offsetInEndSection": 1241,
                    "text": "In particular, JAK inhibitors are oral compounds characterized by short half-life, low antigenicity and the ability to dampen several pro-inflammatory pathways simultaneously.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32873116",
                    "offsetInBeginSection": 685,
                    "offsetInEndSection": 864,
                    "text": "Tofacitinib is an oral pan-JAK inhibitor, primarily of JAK1 and JAK3, that was recently approved by the Food and Drug Administration (FDA) for the chronic treatment of UC in 2018.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31227590",
                    "offsetInBeginSection": 801,
                    "offsetInEndSection": 905,
                    "text": "Tofacitinib, a pan-JAK inhibitor, has been recently approved for the treatment of moderate-to-severe UC.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Please list the Janus Kinase inhibitors used to treat Inflammatory Bowel Disease(IBD)",
            "type": "list",
            "id": "65f1d234c4010b4d78000005",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/20951666",
                "http://www.ncbi.nlm.nih.gov/pubmed/11237682",
                "http://www.ncbi.nlm.nih.gov/pubmed/34851148",
                "http://www.ncbi.nlm.nih.gov/pubmed/23085605",
                "http://www.ncbi.nlm.nih.gov/pubmed/29953259",
                "http://www.ncbi.nlm.nih.gov/pubmed/21752954",
                "http://www.ncbi.nlm.nih.gov/pubmed/29174677",
                "http://www.ncbi.nlm.nih.gov/pubmed/20838412",
                "http://www.ncbi.nlm.nih.gov/pubmed/23116110",
                "http://www.ncbi.nlm.nih.gov/pubmed/38034030"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20951666",
                    "offsetInBeginSection": 687,
                    "offsetInEndSection": 818,
                    "text": "This method has been shown to significantly augment the transfection efficacy and the subsequent vaccine-specific immune responses.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20951666",
                    "offsetInBeginSection": 477,
                    "offsetInEndSection": 686,
                    "text": "One novel in vivo delivery method for plasmid vaccines is electroporation, which is the application of short pulses of electric current immediately after, and at the site of, an injection of a genetic vaccine.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11237682",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 136,
                    "text": "Naked DNA injection with electropermeabilization (EP) is a promising method for nucleic acid vaccination (NAV) and in vivo gene therapy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11237682",
                    "offsetInBeginSection": 285,
                    "offsetInEndSection": 471,
                    "text": "This study demonstrates that in vivo skin EP may be used to increase transgene expression up to an average of 83-fold relative to naked DNA injection (50 microg DNA per dose, P < 0.005).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34851148",
                    "offsetInBeginSection": 434,
                    "offsetInEndSection": 744,
                    "text": "Here, we examined the protective efficacy of the 4pox DNA vaccine delivered by intramuscular (i.m.) electroporation (EP) in rabbits challenged with aerosolized rabbitpox virus (RPXV), a model that recapitulates the respiratory route of exposure and low dose associated with natural smallpox exposure in humans.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23085605",
                    "offsetInBeginSection": 193,
                    "offsetInEndSection": 404,
                    "text": "Two main strategies to increase DNA-based vaccine potency are the employment of immuno-adjuvants such as heat shock proteins (HSPs) and a method of improving the delivery of naked plasmid DNA by electroporation.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23085605",
                    "offsetInBeginSection": 651,
                    "offsetInEndSection": 903,
                    "text": "We found that subcutaneous DNA injection with E7-CT (gp96) followed by electroporation generates the significant E7-specific IFN- immune responses as well as the best protective effects in vaccinated mice as compared to E7 or E7-NT (gp96) DNA vaccines.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29953259",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 198,
                    "text": "The immune responses elicited following delivery of DNA vaccines to the skin has previously been shown to be significantly enhanced by the addition of electroporation (EP) to the treatment protocol.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29953259",
                    "offsetInBeginSection": 294,
                    "offsetInEndSection": 529,
                    "text": "In addition to increasing the levels of in vivo transfection, the physical insult induced by EP is associated with activation of innate pathways which are believed to mediate an adjuvant effect, further enhancing DNA vaccine responses.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21752954",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 163,
                    "text": "In vivo electroporation (EP) has proven to significantly increase plasmid transfection efficiency and to augment immune responses after immunization with plasmids.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is the relationship between  Electroporation (EP) and DNA vaccines?",
            "type": "factoid",
            "id": "65f494d7c4010b4d78000013",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/18334131",
                "http://www.ncbi.nlm.nih.gov/pubmed/33075081",
                "http://www.ncbi.nlm.nih.gov/pubmed/30507696",
                "http://www.ncbi.nlm.nih.gov/pubmed/33104035",
                "http://www.ncbi.nlm.nih.gov/pubmed/18254031",
                "http://www.ncbi.nlm.nih.gov/pubmed/23553671",
                "http://www.ncbi.nlm.nih.gov/pubmed/17541998",
                "http://www.ncbi.nlm.nih.gov/pubmed/36806514",
                "http://www.ncbi.nlm.nih.gov/pubmed/31588416",
                "http://www.ncbi.nlm.nih.gov/pubmed/24305455"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18334131",
                    "offsetInBeginSection": 588,
                    "offsetInEndSection": 694,
                    "text": "Corticosteroid therapy (prednisone and deflazacort) is the only effective pharmacologic treatment for DMD.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33075081",
                    "offsetInBeginSection": 489,
                    "offsetInEndSection": 628,
                    "text": "Among corticosteroid regimens, either deflazacort or prednisone weekend dosing was preferred when payer requirements do not dictate choice.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18334131",
                    "offsetInBeginSection": 695,
                    "offsetInEndSection": 843,
                    "text": "Daily prednisone treatment increases muscle strength and function, improves pulmonary function, and significantly slows the progression of weakness.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30507696",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 240,
                    "text": "Glucocorticoid therapy is currently the most widely used treatment for Duchenne muscular dystrophy (DMD), having consistently shown to prolong ambulation by 2 years, reduce the frequency of scoliosis, and improve cardiorespiratory function.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33104035",
                    "offsetInBeginSection": 100,
                    "offsetInEndSection": 272,
                    "text": "Glucocorticoid steroids such as prednisone and deflazacort are recommended for treating Duchenne Muscular Dystrophy where their use prolongs ambulation and life expectancy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18254031",
                    "offsetInBeginSection": 1137,
                    "offsetInEndSection": 1282,
                    "text": "Types of interventions: glucocorticoids such as prednisone, prednisolone, deflazacort or others, with a minimum treatment period of three months.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23553671",
                    "offsetInBeginSection": 274,
                    "offsetInEndSection": 470,
                    "text": "The current treatment options are limited to physiotherapy and corticosteroids, and although they provide a substantial improvement in affected children, they only slow the course of the disorder.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17541998",
                    "offsetInBeginSection": 397,
                    "offsetInEndSection": 631,
                    "text": "The two main steroids used are prednisone/prednisolone and deflazacort. They are probably equally effective in stabilizing muscle strength but may have different side-effect profiles; for instance, deflazacort causes less weight gain.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36806514",
                    "offsetInBeginSection": 1016,
                    "offsetInEndSection": 1241,
                    "text": "Earlier substantial steroid exposure was associated with greater TFT velocities while the moderate progression class was observed to have the largest difference in performance between boys treated early with steroids vs. not.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31588416",
                    "offsetInBeginSection": 301,
                    "offsetInEndSection": 478,
                    "text": "Glucocorticoids are the only pharmacological agents known to alter the natural progression of the disease by prolonging ambulation, reducing scoliosis, and assisted ventilation.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What types of glucosteroids are used for the management of Duchenne muscular dystrophy?",
            "type": "list",
            "id": "64414bdb57b1c7a315000058",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [],
            "snippets": [],
            "body": "What medication were tested in the PEMMELA trial?",
            "type": "list",
            "id": "65d373e21930410b13000049",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/30157428"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30157428",
                    "offsetInBeginSection": 386,
                    "offsetInEndSection": 578,
                    "text": "We show that this is due to bacterial accumulation in the lamina propria and present evidence that the underlying mechanism is bacterial induction of prostaglandin production by myeloid cells.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30157428",
                    "offsetInBeginSection": 579,
                    "offsetInEndSection": 742,
                    "text": "Moreover, we show that similar events in the normal colonic mucosa lead to reductions in Tuft cells, goblet cells, and the mucus barrier of the colonic epithelium.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is the pathophysiological mechanism by which the microbiota produce malignant lesions in colonic mucosa?",
            "type": "summary",
            "id": "65f77328c4010b4d78000023",
            "ideal_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/25674580",
                "http://www.ncbi.nlm.nih.gov/pubmed/33237151",
                "http://www.ncbi.nlm.nih.gov/pubmed/26428261",
                "http://www.ncbi.nlm.nih.gov/pubmed/34069006",
                "http://www.ncbi.nlm.nih.gov/pubmed/37780902",
                "http://www.ncbi.nlm.nih.gov/pubmed/11747723",
                "http://www.ncbi.nlm.nih.gov/pubmed/17825434",
                "http://www.ncbi.nlm.nih.gov/pubmed/32705126",
                "http://www.ncbi.nlm.nih.gov/pubmed/28464334",
                "http://www.ncbi.nlm.nih.gov/pubmed/26886728"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25674580",
                    "offsetInBeginSection": 158,
                    "offsetInEndSection": 222,
                    "text": "Rotaviruses, caliciviruses and astroviruses are the main causes.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33237151",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 165,
                    "text": "Host shifts, when a cross-species transmission of a pathogen can lead to successful infections, are the main cause of emerging infectious diseases, such as COVID-19.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26428261",
                    "offsetInBeginSection": 124,
                    "offsetInEndSection": 405,
                    "text": "RVA shows vast diversity and a variety of human strains share genetic and antigenic features with animal origin RVA strains. This finding suggests that interspecies transmission is an important mechanism of rotavirus evolution and contributes to the diversity of human RVA strains.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34069006",
                    "offsetInBeginSection": 75,
                    "offsetInEndSection": 278,
                    "text": "While the transmission in developing countries is dominated by fecal-oral route via drinking contaminated water, the zoonotic transmission is the major route of HEV infection in industrialized countries.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37780902",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 103,
                    "text": "Viral hepatitis E, a major cause of acute viral hepatitis in adults, is a global public health problem.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11747723",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 212,
                    "text": "Hepatitis E virus (HEV), a major cause of viral hepatitis in much of the developing world, has recently been detected in swine in North America and Asia, raising concern about potential for zoonotic transmission.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17825434",
                    "offsetInBeginSection": 342,
                    "offsetInEndSection": 492,
                    "text": "An alternative, direct route of infection, from animals to humans (zoonotic transmission) is suspected to be the cause of recent cases of hepatitis E.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32705126",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 168,
                    "text": "Pigs are considered the main reservoir of genotypes 3 and 4 of hepatitis E virus (HEV), which is the major cause of acute hepatitis of viral origin in humans worldwide.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28464334",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 113,
                    "text": "Hepatitis E virus (HEV) is a major cause of acute hepatitis worldwide, primarily transmitted by fecal-oral route.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26886728",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 94,
                    "text": "Hepatitis E virus is a major cause of outbreaks as well as sporadic hepatitis cases worldwide.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is the main cause of spillover events?",
            "type": "factoid",
            "id": "65f8447fc4010b4d78000043",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/9285071"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9285071",
                    "offsetInBeginSection": 1059,
                    "offsetInEndSection": 1165,
                    "text": "A 8-week B13/L2-supplementation lead to a detectable carotenodermia whereas the B3/L3-supplementation not.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "is carotenodermia caused by an excess of lycopene in the diet?",
            "type": "yesno",
            "id": "65ef83acdffffb9b6b000002",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28066556",
                "http://www.ncbi.nlm.nih.gov/pubmed/26440417",
                "http://www.ncbi.nlm.nih.gov/pubmed/37809981",
                "http://www.ncbi.nlm.nih.gov/pubmed/31133409",
                "http://www.ncbi.nlm.nih.gov/pubmed/31325800",
                "http://www.ncbi.nlm.nih.gov/pubmed/20888642",
                "http://www.ncbi.nlm.nih.gov/pubmed/36960117",
                "http://www.ncbi.nlm.nih.gov/pubmed/23311493",
                "http://www.ncbi.nlm.nih.gov/pubmed/14629525",
                "http://www.ncbi.nlm.nih.gov/pubmed/15921881"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28066556",
                    "offsetInBeginSection": 192,
                    "offsetInEndSection": 413,
                    "text": "A Numerical Rating Scale (NRS) ranging from 0 to 10 (0, no pain; 10, maximum pain), which is based on a patient's self-report, is the gold standard for pain evaluation in patients who can communicate their pain intensity.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28066556",
                    "offsetInBeginSection": 628,
                    "offsetInEndSection": 872,
                    "text": "The Behavioral Pain Scale (BPS) and Critical Care Pain Observation Tool (CPOT) have been developed for pain assessment in patients who cannot self-report their pain intensity, and recent research has confirmed their efficacy in clinical trials.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26440417",
                    "offsetInBeginSection": 818,
                    "offsetInEndSection": 960,
                    "text": "Visual Analog Scale and Numerical Rating Scale were used in 57% (n = 48; 99.3% CI, 41%-72%) and 48% (n = 40; 99.3% CI, 33%-64%), respectively.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37809981",
                    "offsetInBeginSection": 1082,
                    "offsetInEndSection": 1163,
                    "text": "Among these instruments, the numeric rating scale was the most commonly employed.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31133409",
                    "offsetInBeginSection": 909,
                    "offsetInEndSection": 1072,
                    "text": "A total of 81.7% of the nurses used a pain assessment tool with patients unable to communicate, and the Adult Nonverbal Pain Scale was the most commonly used tool.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26440417",
                    "offsetInBeginSection": 1156,
                    "offsetInEndSection": 1379,
                    "text": "In the ICUs that used behaviorally based scoring systems, the Critical Care Pain Observation Tool and Behavioral Pain Scale (BPS) were used in 6% (n = 5; 99.5% CI, 1.1%-17%) and 5% (n = 4; 99.5% CI, 0.1%-15%), respectively.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37809981",
                    "offsetInBeginSection": 1164,
                    "offsetInEndSection": 1367,
                    "text": "Furthermore, 77% of the nurses (35 in total) used a pain assessment tool for patients who were unable to communicate, with the Adult Nonverbal Pain Scale being the most frequently used tool in this case.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31325800",
                    "offsetInBeginSection": 984,
                    "offsetInEndSection": 1106,
                    "text": "Twelve pain scales, including the target population, scoring, psychometric properties, and clinical utility are described.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20888642",
                    "offsetInBeginSection": 210,
                    "offsetInEndSection": 345,
                    "text": "The Nonverbal Pain Assessment Tool (NPAT), a behavioral pain assessment tool, was developed for the nonverbal adult patient in the ICU.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31325800",
                    "offsetInBeginSection": 808,
                    "offsetInEndSection": 870,
                    "text": "Seven behavioral scales and five self-report scales were used.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What are the most commonly used pain scales for the measurement of pain in ICU?",
            "type": "list",
            "id": "644108b157b1c7a315000053",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/37811660",
                "http://www.ncbi.nlm.nih.gov/pubmed/24945654",
                "http://www.ncbi.nlm.nih.gov/pubmed/34965028",
                "http://www.ncbi.nlm.nih.gov/pubmed/37245863",
                "http://www.ncbi.nlm.nih.gov/pubmed/36304386",
                "http://www.ncbi.nlm.nih.gov/pubmed/29634881",
                "http://www.ncbi.nlm.nih.gov/pubmed/38016088",
                "http://www.ncbi.nlm.nih.gov/pubmed/17352720",
                "http://www.ncbi.nlm.nih.gov/pubmed/35502157",
                "http://www.ncbi.nlm.nih.gov/pubmed/37108838"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37811660",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 119,
                    "text": "Prurigo nodularis (PN) is a chronic inflammatory skin condition that presents with pruritus and hyperkeratotic nodules.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24945654",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 107,
                    "text": "Prurigo nodularis (PN) is an eruption of lichenified or excoriated nodules related to intractable pruritus.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34965028",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 153,
                    "text": "Prurigo nodularis (PN) is a chronic dermatologic condition manifesting as multiple papulonodular lesions occurring on the background of intense pruritus.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37245863",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 118,
                    "text": "Prurigo nodularis (PN) is an understudied inflammatory skin disease characterized by pruritic, hyperkeratotic nodules.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36304386",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 171,
                    "text": "Prurigo nodularis (PN) is a chronic skin disease that manifests with severe itchy, firm, hyperkeratotic nodules distributed on the trunk and the extremities symmetrically.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29634881",
                    "offsetInBeginSection": 97,
                    "offsetInEndSection": 205,
                    "text": "It occurs in patients with chronic itch and is characterized by multiple hyperkeratotic papules and nodules.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38016088",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 114,
                    "text": "Prurigo nodularis (PN) is a chronic inflammatory skin condition characterized by the presence of pruritic nodules.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17352720",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 118,
                    "text": "Prurigo nodularis is an intensely pruritic dermatosis characterized by lichenified and excoriated papules and nodules.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35502157",
                    "offsetInBeginSection": 141,
                    "offsetInEndSection": 348,
                    "text": "The basis of this skin condition is immunological dysregulation and neural amplification, driven by T-lymphocytes, mast cells, eosinophilic granulocytes, macrophages, and cytokines mediating itchy processes.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37108838",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 127,
                    "text": "Prurigo nodularis (PN) is a chronic condition characterized by the presence of nodular lesions accompanied by intense pruritus.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is prurigo nodularis?",
            "type": "summary",
            "id": "65f1eb84c4010b4d78000008",
            "ideal_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/34561299",
                "http://www.ncbi.nlm.nih.gov/pubmed/28705153",
                "http://www.ncbi.nlm.nih.gov/pubmed/31764257",
                "http://www.ncbi.nlm.nih.gov/pubmed/20931624"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34561299",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 105,
                    "text": "Tenofovir (TFV) is a key component of human immunodeficiency virus (HIV) pre-exposure prophylaxis (PrEP).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28705153",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 128,
                    "text": "Tenofovir disoproxil fumarate (TDF) is key component of pre-exposure prophylaxis (PrEP) and antiretroviral therapy (ART) for HIV",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31764257",
                    "offsetInBeginSection": 927,
                    "offsetInEndSection": 1244,
                    "text": "The third unpacks the dynamics of a novel strategy of delivering oral pre-exposure prophylaxis and ART to HIV serodiscordant couples, showing how the organization of services positively impacted participating couples, enabling them to use oral pre-exposure prophylaxis and ART effectively to prevent HIV transmission.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20931624",
                    "offsetInBeginSection": 1344,
                    "offsetInEndSection": 1555,
                    "text": "Altogether 10 coumarins have been identified and five of them including xanthotoxol, osthenol, oxypeucedanin hydrate, byakangelicin and imperatorin were deemed as target components for the preparative isolation.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Which are the two main active ingredients of the standard PrEP (Pre-Exposure Prophylaxis)?",
            "type": "list",
            "id": "65f85231c4010b4d7800004d",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/32307747",
                "http://www.ncbi.nlm.nih.gov/pubmed/10069393",
                "http://www.ncbi.nlm.nih.gov/pubmed/16083495",
                "http://www.ncbi.nlm.nih.gov/pubmed/25360677",
                "http://www.ncbi.nlm.nih.gov/pubmed/28949267"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32307747",
                    "offsetInBeginSection": 494,
                    "offsetInEndSection": 727,
                    "text": "Curcumin is a natural phenolic compound which shows potent anticancer activities in different tumors, alone or as an adjuvant with other antitumor drugs to prevent or inhibit the survival and cancer progression by various mechanisms.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32307747",
                    "offsetInBeginSection": 1012,
                    "offsetInEndSection": 1227,
                    "text": "It has been demonstrated that curcumin regulates signaling pathways in cancer cells, reduces the expression of proteins related to drug resistance, and increases the performance of antitumor drugs at various levels.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32307747",
                    "offsetInBeginSection": 1228,
                    "offsetInEndSection": 1340,
                    "text": "Curcumin reverses multidrug resistance mechanisms and increases sensitivity of resistance cells to chemotherapy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10069393",
                    "offsetInBeginSection": 137,
                    "offsetInEndSection": 210,
                    "text": "Curcumin inhibited AK-5 tumor growth and induced apoptosis in AK-5 cells.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16083495",
                    "offsetInBeginSection": 1195,
                    "offsetInEndSection": 1358,
                    "text": "Identified agents increased p53 levels and induced apoptosis in tumor cells as determined by annexin V-FITC binding, DNA fragmentation and caspase activity assays.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25360677",
                    "offsetInBeginSection": 329,
                    "offsetInEndSection": 556,
                    "text": "Curcumin, a natural polyphenol compound found in the spice turmeric, is known for its anti-cancer properties at doses over 10 M, and often at 50 M, and it exerts its effects on cancer cells in part by activation of MAP kinases.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28949267",
                    "offsetInBeginSection": 1271,
                    "offsetInEndSection": 1424,
                    "text": "But curcumin-loaded SLN exhibited antioxidant properties, substantiating the conclusions that curcumin's effect in cancer cells is highly dose dependent.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25360677",
                    "offsetInBeginSection": 557,
                    "offsetInEndSection": 771,
                    "text": "In contrast, we found that low-dose curcumin (0.5 M) applied to OECs strikingly modulated the dynamic morphology, increased the rate of migration by up to 4-fold, and promoted significant proliferation of the OECs.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25360677",
                    "offsetInBeginSection": 772,
                    "offsetInEndSection": 874,
                    "text": "Most dramatically, low-dose curcumin stimulated a 10-fold increase in the phagocytic activity of OECs.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Can Antioxidant curcumin kill tumor cells?",
            "type": "yesno",
            "id": "65f1dadac4010b4d78000007",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/36412389",
                "http://www.ncbi.nlm.nih.gov/pubmed/32004738",
                "http://www.ncbi.nlm.nih.gov/pubmed/23483049",
                "http://www.ncbi.nlm.nih.gov/pubmed/35166475",
                "http://www.ncbi.nlm.nih.gov/pubmed/20220448",
                "http://www.ncbi.nlm.nih.gov/pubmed/12533338",
                "http://www.ncbi.nlm.nih.gov/pubmed/17330185",
                "http://www.ncbi.nlm.nih.gov/pubmed/22450762",
                "http://www.ncbi.nlm.nih.gov/pubmed/31690266",
                "http://www.ncbi.nlm.nih.gov/pubmed/88935"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36412389",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 184,
                    "text": "Meningeal melanomatosis is an infrequent tumor originating from the melanocytes in the leptomeninges and one of the recognized primary melanocytic tumors of the central nervous system.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32004738",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 158,
                    "text": "Primary meningeal melanomatosis is a rare leptomeningeal tumor, and the diagnosis is challenging due to nonspecific clinical symptoms and radiologic findings.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23483049",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 207,
                    "text": "Primary meningeal melanomatosis is a rare, aggressive variant of primary malignant melanoma of the central nervous system, which arises from melanocytes within the leptomeninges and carries a poor prognosis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35166475",
                    "offsetInBeginSection": 158,
                    "offsetInEndSection": 368,
                    "text": "In case of diffusely invasive lesions of the pia mater with a tumor of melanocytic origin (without signs of extracranial metastases), the tumors are classified as primary diffuse meningeal melanomatosis (PDMM).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20220448",
                    "offsetInBeginSection": 299,
                    "offsetInEndSection": 451,
                    "text": "We report on a young patient with primary diffuse meningeal melanomatosis who presented with papilledema, flaccid paraparesis, and cognitive impairment.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12533338",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 141,
                    "text": "We report a case of primary diffuse meningeal melanomatosis, a rare variant of primary malignant melanoma of the CNS, in a 68-year-old woman.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20220448",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 298,
                    "text": "Primary diffuse meningeal melanomatosis can clinically mimic a wide variety of other conditions, including lymphoma, leukemia, neurosarcoidosis, metastatic carcinoma, acute disseminated encephalomyelitis, subacute meningitis, viral encephalitis, and idiopathic hypertrophic cranial pachymeningitis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17330185",
                    "offsetInBeginSection": 630,
                    "offsetInEndSection": 788,
                    "text": "Despite the use of detailed diagnostic procedures, the correct diagnosis of primary diffuse meningeal melanomatosis was established at postmortem examination.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32004738",
                    "offsetInBeginSection": 817,
                    "offsetInEndSection": 921,
                    "text": "Pathohistologic results of biopsied meninges confirmed the diagnosis of diffuse meningeal melanomatosis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22450762",
                    "offsetInBeginSection": 68,
                    "offsetInEndSection": 175,
                    "text": "The spread of melanoma cells primarily into the meningeal layers is referred to as meningeal melanomatosis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is Primary Diffuse Meningeal Melanomatosis?",
            "type": "summary",
            "id": "65d129621930410b1300002e",
            "ideal_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/37889055"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37889055",
                    "offsetInBeginSection": 839,
                    "offsetInEndSection": 998,
                    "text": "Its mechanism of action includes promoting adiponectin levels, enhancing insulin sensitivity, increasing triglyceride uptake, and reducing de novo lipogenesis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37889055",
                    "offsetInBeginSection": 720,
                    "offsetInEndSection": 838,
                    "text": "PGZ, through its extended half-life of 55 to 100 hours, has evidenced significant improvements in metabolic functions.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is the mechanism of action of Pegozafermin?",
            "type": "summary",
            "id": "65cfab681930410b13000012",
            "ideal_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/36237717",
                "http://www.ncbi.nlm.nih.gov/pubmed/29116603",
                "http://www.ncbi.nlm.nih.gov/pubmed/34933094",
                "http://www.ncbi.nlm.nih.gov/pubmed/9063742",
                "http://www.ncbi.nlm.nih.gov/pubmed/16773507",
                "http://www.ncbi.nlm.nih.gov/pubmed/31944285",
                "http://www.ncbi.nlm.nih.gov/pubmed/2829705",
                "http://www.ncbi.nlm.nih.gov/pubmed/21167962",
                "http://www.ncbi.nlm.nih.gov/pubmed/33894360",
                "http://www.ncbi.nlm.nih.gov/pubmed/7715756"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36237717",
                    "offsetInBeginSection": 302,
                    "offsetInEndSection": 447,
                    "text": "The cause of Leigh syndrome is DNA mutation. Approximately 75% of patients have nuclear DNA mutations while 25% have mitochondrial DNA mutations.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29116603",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 135,
                    "text": "Leigh syndrome (LS), subacute necrotizing encephalomyelopathy is caused by various genetic defects, including m.9185T>C MTATP6 variant.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34933094",
                    "offsetInBeginSection": 164,
                    "offsetInEndSection": 353,
                    "text": "Leigh syndrome is the most common clinical presentation of pediatric mitochondrial disease, typically appearing in the first few years of life, and involving severe multisystem pathologies.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9063742",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 197,
                    "text": "A generalized defect of complex IV (cytochrome C oxidase, COX) is frequently found in subacute necrotizing encephalomyelopathy (Leigh's syndrome), the most common mitochondrial disorder in infancy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16773507",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 146,
                    "text": "Cytochrome c oxidase deficiency (COX) is the most frequent cause of Leigh syndrome (LS), a mitochondrial subacute necrotizing encephalomyelopathy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16773507",
                    "offsetInBeginSection": 147,
                    "offsetInEndSection": 298,
                    "text": "Most of these LS (COX-) patients show mutations in SURF1 on chromosome 9 (9q34), which encodes a protein essential for the assembly of the COX complex.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31944285",
                    "offsetInBeginSection": 395,
                    "offsetInEndSection": 637,
                    "text": "patients with deficiencies in the FAO enzyme short-chain enoyl-CoA hydratase 1 (ECHS1) are typically diagnosed with Leigh syndrome, a lethal form of subacute necrotizing encephalomyelopathy that is normally associated with OXPHOS dysfunction.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2829705",
                    "offsetInBeginSection": 354,
                    "offsetInEndSection": 591,
                    "text": "An isolated defect of cytochrome c oxidase (COX) activity was found in brain (decrease of activity to 15 to 39% of the normal mean), muscle (9 to 20%), kidney (1 to 67%), and in the 1 available heart (4%) from a patient with cardiopathy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21167962",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 141,
                    "text": "Surf1 gene mutations were detected as a main cause for Leigh syndrome (LS), also known as infantile subacute necrotizing encephalomyelopathy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33894360",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 134,
                    "text": "Leigh syndrome is a progressive neurodegenerative syndrome caused by multiple mitochondrial DNA and nuclear DNA pathological variants.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is the cause of Leigh syndrome?",
            "type": "factoid",
            "id": "6451007857b1c7a315000093",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24390401",
                "http://www.ncbi.nlm.nih.gov/pubmed/12834681",
                "http://www.ncbi.nlm.nih.gov/pubmed/17937041",
                "http://www.ncbi.nlm.nih.gov/pubmed/18700453",
                "http://www.ncbi.nlm.nih.gov/pubmed/15281969",
                "http://www.ncbi.nlm.nih.gov/pubmed/18366862",
                "http://www.ncbi.nlm.nih.gov/pubmed/15702319",
                "http://www.ncbi.nlm.nih.gov/pubmed/37696676",
                "http://www.ncbi.nlm.nih.gov/pubmed/19661835",
                "http://www.ncbi.nlm.nih.gov/pubmed/26949612"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24390401",
                    "offsetInBeginSection": 1548,
                    "offsetInEndSection": 1671,
                    "text": "CPC is a safe and effective procedure that should be considered if medical treatment has failed to control glaucoma in FUS.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12834681",
                    "offsetInBeginSection": 733,
                    "offsetInEndSection": 887,
                    "text": "Whether this aggressive therapy occurs by medications or by filtering surgery does not seem as important as that the treatment is effective and sustained.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17937041",
                    "offsetInBeginSection": 1288,
                    "offsetInEndSection": 1552,
                    "text": "The results from this study support the concept that the majority of glaucoma patients, who are responding inadequately to other glaucoma therapies, could benefit from a change to travoprost monotherapy or from the addition of travoprost to their existing therapy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18700453",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 361,
                    "text": "Over the past decade, results from prospective, randomized, clinical trials have confirmed the value of reducing intraocular pressure (IOP) in patients with ocular hypertension or primary open-angle glaucoma and have outlined the need to consider a target IOP in an individual glaucomatous patient and not an arbitrary value of 21 mm Hg as classically believed.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15281969",
                    "offsetInBeginSection": 1415,
                    "offsetInEndSection": 1589,
                    "text": "With fewer medications, SLT gives similar intraocular pressure reduction to medical therapy alone in Chinese patients with primary open-angle glaucoma or ocular hypertension.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18366862",
                    "offsetInBeginSection": 1589,
                    "offsetInEndSection": 1676,
                    "text": "Treatment alterations are necessary to achieve sufficient IOP control in some patients.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12834681",
                    "offsetInBeginSection": 888,
                    "offsetInEndSection": 1067,
                    "text": "However, there is not the same strength of evidence for aggressive treatment or even any treatment for most patients with ocular hypertension and for some cases of early glaucoma.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15702319",
                    "offsetInBeginSection": 886,
                    "offsetInEndSection": 1072,
                    "text": "Due to the large individual differences in risk distribution and the very high costs of treating OHT, the question of whether OHT should be treated on principle remains open in the OHTS.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37696676",
                    "offsetInBeginSection": 1371,
                    "offsetInEndSection": 1674,
                    "text": "This study shows that during the time frame in question, patients with glaucoma or ocular hypertension who had an EyeCee One IOL were almost two and a half times more likely to have a postoperative rise of 10 mm Hg or more in IOP following routine cataract surgery, requiring more aggressive management.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19661835",
                    "offsetInBeginSection": 1122,
                    "offsetInEndSection": 1300,
                    "text": "Juvenile-onset Open Angle Glaucoma (JOAG) has been proposed to be a small subset of Primary Open Angle Glaucoma (POAG) and on a continual spectrum of Primary Open Angle Glaucoma.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Should we treat all patients with glaucoma?",
            "type": "yesno",
            "id": "65f85f77c4010b4d78000053",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22114137",
                "http://www.ncbi.nlm.nih.gov/pubmed/19673013",
                "http://www.ncbi.nlm.nih.gov/pubmed/10234894",
                "http://www.ncbi.nlm.nih.gov/pubmed/26703651",
                "http://www.ncbi.nlm.nih.gov/pubmed/16552299",
                "http://www.ncbi.nlm.nih.gov/pubmed/15925649",
                "http://www.ncbi.nlm.nih.gov/pubmed/21710235",
                "http://www.ncbi.nlm.nih.gov/pubmed/37114199",
                "http://www.ncbi.nlm.nih.gov/pubmed/34193094",
                "http://www.ncbi.nlm.nih.gov/pubmed/20229075"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22114137",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 97,
                    "text": "African American colorectal cancer patients have worse survival outcomes than Caucasian patients.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19673013",
                    "offsetInBeginSection": 513,
                    "offsetInEndSection": 608,
                    "text": "Overall, African-Americans are 38% to 43% more likely to die from colon cancer than are Whites.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10234894",
                    "offsetInBeginSection": 618,
                    "offsetInEndSection": 811,
                    "text": "Mortality rates for colon and rectal cancer in Louisiana were comparable to the SEER rates, suggesting Louisiana blacks, once diagnosed, have a poorer survival than their national counterparts.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26703651",
                    "offsetInBeginSection": 934,
                    "offsetInEndSection": 1073,
                    "text": "Blacks were diagnosed at more advanced stages of disease than whites and had an increased risk of death from both colon and rectal cancers.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16552299",
                    "offsetInBeginSection": 1676,
                    "offsetInEndSection": 1861,
                    "text": "The 5-year survival rate for CRC among African Americans improved to 54% during the years 1995-2000, but lagged well behind the 64% survival rate for Whites during the same time period.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19673013",
                    "offsetInBeginSection": 701,
                    "offsetInEndSection": 857,
                    "text": "African Americans tend to be diagnosed at a later stage, to suffer from better differentiated tumors, and to have worse prognosis when compared with Whites.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15925649",
                    "offsetInBeginSection": 1907,
                    "offsetInEndSection": 2033,
                    "text": "The problem has been clearly defined: a higher incidence of and a higher mortality from CRC for African Americans than whites.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21710235",
                    "offsetInBeginSection": 182,
                    "offsetInEndSection": 290,
                    "text": "Survival from CRC in AAs is lower than in Caucasians, and the mean age of CRC development in AAs is younger.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37114199",
                    "offsetInBeginSection": 90,
                    "offsetInEndSection": 214,
                    "text": "Enhanced screening has reduced mortality rates; however, certain populations remain at high risk, notably African Americans.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34193094",
                    "offsetInBeginSection": 1132,
                    "offsetInEndSection": 1235,
                    "text": "In 2016, Blacks had higher mortality rates (17.9), than Whites (15.2), Latinos (10.4) and Asians (8.8).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Do black race patients have worse survival in colorectal cancer?",
            "type": "yesno",
            "id": "65f77236c4010b4d7800001f",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [],
            "snippets": [],
            "body": "When was Havana Syndrome first recognized?",
            "type": "factoid",
            "id": "65f856a1c4010b4d7800004e",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/32353579",
                "http://www.ncbi.nlm.nih.gov/pubmed/36641984",
                "http://www.ncbi.nlm.nih.gov/pubmed/18192684",
                "http://www.ncbi.nlm.nih.gov/pubmed/32485251",
                "http://www.ncbi.nlm.nih.gov/pubmed/22880074",
                "http://www.ncbi.nlm.nih.gov/pubmed/34468172",
                "http://www.ncbi.nlm.nih.gov/pubmed/25130915",
                "http://www.ncbi.nlm.nih.gov/pubmed/32298465"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32353579",
                    "offsetInBeginSection": 102,
                    "offsetInEndSection": 229,
                    "text": "Much effort has been made over the last several decades in vaccine development, but there is no licensed vaccine on the market.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36641984",
                    "offsetInBeginSection": 585,
                    "offsetInEndSection": 696,
                    "text": "Despite an extensive list of attempts to develop a vaccine, no approved vaccine against H. pylori is available.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18192684",
                    "offsetInBeginSection": 133,
                    "offsetInEndSection": 187,
                    "text": "There is no approved vaccine or effective prophylaxis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32485251",
                    "offsetInBeginSection": 232,
                    "offsetInEndSection": 363,
                    "text": "Although several drugs have been announced to be partially effective treatments for this disease, no approved vaccine is available.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32353579",
                    "offsetInBeginSection": 230,
                    "offsetInEndSection": 415,
                    "text": "We have previously reported that oral immunization with H. pylori lysates and double mutant heat-labile toxin (dmLT) affords prophylactic protection against H. pylori infection in mice.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22880074",
                    "offsetInBeginSection": 461,
                    "offsetInEndSection": 537,
                    "text": "Currently, there is no licensed vaccine against NTHi commercially available.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34468172",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 137,
                    "text": "Human norovirus is the leading cause of gastroenteritis worldwide, with no approved vaccine or antiviral treatment to mitigate infection.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25130915",
                    "offsetInBeginSection": 1315,
                    "offsetInEndSection": 1441,
                    "text": "Available HPV vaccines could potentially prevent 77.8% of Bosnian cervical cancer cases (i.e. those associated with HPV16/18).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32298465",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 191,
                    "text": "Factor H binding protein (fHbp) is a key virulence factor of Neisseria meningitidis and a main component of the two licensed vaccines against serogroup B meningococcus (Bexsero and Trumenba).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Is there an approved vaccine against Helicobacter pylori?",
            "type": "yesno",
            "id": "65f86a90c4010b4d78000057",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/36239611",
                "http://www.ncbi.nlm.nih.gov/pubmed/37378532"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36239611",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 257,
                    "text": "The COSMIC-313 phase 3 randomized controlled trial tested the triplet combination of cabozantinib with nivolumab and ipilimumab in comparison with nivolumab plus ipilimumab control as fist-line systemic therapy in metastatic clear cell renal cell carcinoma.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37378532",
                    "offsetInBeginSection": 217,
                    "offsetInEndSection": 434,
                    "text": "The use of triplet combinations with immune checkpoint inhibition with anti-vascular endothelial growth factor tyrosine kinase inhibitors in the front-line setting for metastatic disease (COSMIC313) has been explored.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What medications were tested in the COSMIC-313 trial?",
            "type": "list",
            "id": "65d140e71930410b1300003f",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/37595494",
                "http://www.ncbi.nlm.nih.gov/pubmed/35060440",
                "http://www.ncbi.nlm.nih.gov/pubmed/34551229",
                "http://www.ncbi.nlm.nih.gov/pubmed/31207478",
                "http://www.ncbi.nlm.nih.gov/pubmed/31336704",
                "http://www.ncbi.nlm.nih.gov/pubmed/36847626",
                "http://www.ncbi.nlm.nih.gov/pubmed/37141553",
                "http://www.ncbi.nlm.nih.gov/pubmed/36102132",
                "http://www.ncbi.nlm.nih.gov/pubmed/36094043",
                "http://www.ncbi.nlm.nih.gov/pubmed/32725406"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37595494",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 178,
                    "text": "Tebentafusp is a new T cell receptor bispecific fusion protein and the first approved treatment option for human leucocyte antigen-A*02:01 (HLA-A*02:01) metastatic uveal melanoma",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35060440",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 212,
                    "text": "Tebentafusp is a novel bispecific immune mobilizing T cell receptor (TCR)-based agent developed for the treatment of metastatic uveal melanoma, a highly fatal disease with no currently approved treatment options.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34551229",
                    "offsetInBeginSection": 286,
                    "offsetInEndSection": 471,
                    "text": "Tebentafusp is a bispecific protein consisting of an affinity-enhanced T-cell receptor fused to an anti-CD3 effector that can redirect T cells to target glycoprotein 100-positive cells.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34551229",
                    "offsetInBeginSection": 1912,
                    "offsetInEndSection": 2067,
                    "text": "Treatment with tebentafusp resulted in longer overall survival than the control therapy among previously untreated patients with metastatic uveal melanoma.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31207478",
                    "offsetInBeginSection": 1108,
                    "offsetInEndSection": 1289,
                    "text": "The first of these reagents to reach the clinic, tebentafusp (IMCgp100), has generated demonstrable clinical efficacy in an immunologically cold solid tumour with a high unmet need.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31336704",
                    "offsetInBeginSection": 332,
                    "offsetInEndSection": 571,
                    "text": "Tebentafusp is a novel form of immunotherapy based on the immune-mobilising monoclonal T cell receptor against cancer (ImmTAC) platform, which comprises a soluble T cell receptor that is fused to an anti-CD3 single-chain variable fragment.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36847626",
                    "offsetInBeginSection": 21,
                    "offsetInEndSection": 314,
                    "text": "the U.S. Food and Drug Administration (FDA) approved the use of tebentafusp, a bispecific glycoprotein 100 (gp100) peptide-human leukocyte antigen (HLA)-directed CD3 T-cell activator, for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma (mUM)",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37141553",
                    "offsetInBeginSection": 723,
                    "offsetInEndSection": 867,
                    "text": "Tebentafusp, a bispecific molecule, is the first treatment to improve overall survival (OS) in patients with HLA A*02:01-positive metastatic UM.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36102132",
                    "offsetInBeginSection": 87,
                    "offsetInEndSection": 174,
                    "text": "Tebentafusp recently became the first FDA-approved agent for metastatic uveal melanoma.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36094043",
                    "offsetInBeginSection": 776,
                    "offsetInEndSection": 1054,
                    "text": "The first systemic immunotherapy specifically for metastatic uveal melanoma was approved this year. This medication, tebentafusp, is likely to improve life expectancy for all patients with metastatic melanoma assuming they have appropriate human leukocyte antigen (HLA) markers.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What disease can be treated with Tebentafusp?",
            "type": "factoid",
            "id": "65cec1fb1930410b13000005",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/26198690",
                "http://www.ncbi.nlm.nih.gov/pubmed/26847196"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26198690",
                    "offsetInBeginSection": 900,
                    "offsetInEndSection": 1063,
                    "text": "In multivariate analysis, in both sexes, never having been tested was significantly associated with an age younger or older than the middle-age group (30-44 years)",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26847196",
                    "offsetInBeginSection": 1255,
                    "offsetInEndSection": 1390,
                    "text": "MSW with no history of HIV screening were more likely to be tested positive for HIV compared to those with a previous HIV-negative test",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Which age group should never be tested for HIV infection?",
            "type": "factoid",
            "id": "65f86ba3c4010b4d78000059",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28395555",
                "http://www.ncbi.nlm.nih.gov/pubmed/26785741",
                "http://www.ncbi.nlm.nih.gov/pubmed/32942879",
                "http://www.ncbi.nlm.nih.gov/pubmed/26868931",
                "http://www.ncbi.nlm.nih.gov/pubmed/26935836",
                "http://www.ncbi.nlm.nih.gov/pubmed/28618994",
                "http://www.ncbi.nlm.nih.gov/pubmed/27186592",
                "http://www.ncbi.nlm.nih.gov/pubmed/28750828",
                "http://www.ncbi.nlm.nih.gov/pubmed/35911507",
                "http://www.ncbi.nlm.nih.gov/pubmed/26886466"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28395555",
                    "offsetInBeginSection": 504,
                    "offsetInEndSection": 852,
                    "text": "In 2015, the Food and Drug Administration and the European Medicines Agency approved alirocumab (Praluent; Sanofi), a fully human monoclonal antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9), for the treatment of hypercholesterolaemic patients unable to meet LDL-C targets, as an adjunct to diet in addition/alternative to LLT.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26785741",
                    "offsetInBeginSection": 214,
                    "offsetInEndSection": 349,
                    "text": "Alirocumab has been shown to lower low density lipoprotein cholesterol by 45-62% with a safety profile generally comparable to placebo.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32942879",
                    "offsetInBeginSection": 746,
                    "offsetInEndSection": 978,
                    "text": "It has been shown that alirocumab exerts favorable effect on atherogenic lipoproteins (i.e. decrease of concentrations of LDL cholesterol by more than 50%) both in monotherapy and in combination with statins or other hypolipidemics.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32942879",
                    "offsetInBeginSection": 315,
                    "offsetInEndSection": 405,
                    "text": "Alirocumab is a specific antibody against PCSK9, manufactured using recombinant technique.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26868931",
                    "offsetInBeginSection": 214,
                    "offsetInEndSection": 416,
                    "text": "Both drugs have marketing authorisation for the treatment of primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia and are administered by subcutaneous injection.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26935836",
                    "offsetInBeginSection": 174,
                    "offsetInEndSection": 341,
                    "text": "Across ten phase III studies from the ODYSSEY clinical trial program in patients with heterozygous familial hypercholesterolemia (heFH) or nonfamilial hypercholesterol",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28618994",
                    "offsetInBeginSection": 1063,
                    "offsetInEndSection": 1619,
                    "text": "Recently the fully human monoclonal antibodies against proprotein convertase subtilisin/kexin 9 (PCSK9), alirocumab (Praluent) and evolocumab (Repatha), which have been shown to decrease LDL-C by up to 70% have been approved in Europe for use in patients with primary hypercholesterolemia not at LDL-C target while on maximally tolerated lipid-lowering therapy and specifically for patients with statin intolerance and in the USA for patients with atherosclerotic cardiovascular disease or familial hypercholesterolemia requiring additional LDL-C lowering.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27186592",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 485,
                    "text": "In 2015 the U.S. Food and Drug Administration approved the first two proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, alirocumab (Praluent; Sanofi/ Regeneron) and evolocumab (Repatha; Amgen), for use in patients with heterozygous and homozygous familial hypercholesterolemia and for patients intolerant of statins or those with a major risk of cardiovascular disease (CVD) but unable to lower their LDL cholesterol (LDL-C) to optimal levels with statins and ezetimibe.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28750828",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 154,
                    "text": "The proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab has been shown to substantially reduce low-density lipoprotein cholesterol (LDL-C).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35911507",
                    "offsetInBeginSection": 379,
                    "offsetInEndSection": 660,
                    "text": "In this prospective nation-wide cohort study, we aimed to investigate the patient profile and routine clinical efficacy and safety of alirocumab in 207 patients with ASCVD or heterozygous familial hypercholesterolemia and increased LDL-C despite maximally tolerated statin therapy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is the indication for Alirocumab?",
            "type": "factoid",
            "id": "65f70b9cc4010b4d7800001c",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/25118385",
                "http://www.ncbi.nlm.nih.gov/pubmed/17610952",
                "http://www.ncbi.nlm.nih.gov/pubmed/21994610",
                "http://www.ncbi.nlm.nih.gov/pubmed/22815803",
                "http://www.ncbi.nlm.nih.gov/pubmed/21046175",
                "http://www.ncbi.nlm.nih.gov/pubmed/36920694",
                "http://www.ncbi.nlm.nih.gov/pubmed/30332733",
                "http://www.ncbi.nlm.nih.gov/pubmed/26656687",
                "http://www.ncbi.nlm.nih.gov/pubmed/27497688",
                "http://www.ncbi.nlm.nih.gov/pubmed/24713118"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25118385",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 77,
                    "text": "Ebola virus (EBOV) and Marburg virus (MARV) belong to the family Filoviridae.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17610952",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 95,
                    "text": "Ebola viruses (EBOV) and Marburg virus belong to the family Filoviridae, order Mononegavirales.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21994610",
                    "offsetInBeginSection": 121,
                    "offsetInEndSection": 303,
                    "text": "The only two genera of the Filoviridae family, Marburg virus (MARV) and Ebola virus (EBOV), comprise the main etiologic agents of severe hemorrhagic fever outbreaks in central Africa",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22815803",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 144,
                    "text": "Ebola virus (EBOV) and Marburg virus (MARV) belong to the family Filoviridae and cause severe hemorrhagic fever in humans and nonhuman primates.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21046175",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 204,
                    "text": "The taxonomy of the family Filoviridae (marburgviruses and ebolaviruses) has changed several times since the discovery of its members, resulting in a plethora of species and virus names and abbreviations.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36920694",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 125,
                    "text": "Marburg virus (MARV) and Ebola virus (EBOV) of the Filoviridae family are the most lethal viruses in terms of mortality rate.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30332733",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 153,
                    "text": "Members of the family Filoviridae, including Ebola virus (EBOV) and Marburg virus (MARV), cause severe hemorrhagic fever in humans and nonhuman primates.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26656687",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 113,
                    "text": "Marburg virus (MARV), a member of the filovirus family, causes severe hemorrhagic fever with up to 90% lethality.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27497688",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 94,
                    "text": "Marburg virus (MARV), a member of the Filoviridae family that also includes Ebola virus (EBOV)",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24713118",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 78,
                    "text": "Marburg virus (MARV) and Ebola virus (EBOV), members of the family Filoviridae",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Is Marburg virus a member of the family of the Ebola virus (Filoviridae)?",
            "type": "yesno",
            "id": "65f86f03c4010b4d7800005b",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/8965601",
                "http://www.ncbi.nlm.nih.gov/pubmed/2190745",
                "http://www.ncbi.nlm.nih.gov/pubmed/3949445",
                "http://www.ncbi.nlm.nih.gov/pubmed/2588201",
                "http://www.ncbi.nlm.nih.gov/pubmed/2524845",
                "http://www.ncbi.nlm.nih.gov/pubmed/3058373",
                "http://www.ncbi.nlm.nih.gov/pubmed/8179003",
                "http://www.ncbi.nlm.nih.gov/pubmed/19648670",
                "http://www.ncbi.nlm.nih.gov/pubmed/2960110",
                "http://www.ncbi.nlm.nih.gov/pubmed/2978041"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8965601",
                    "offsetInBeginSection": 339,
                    "offsetInEndSection": 449,
                    "text": "Domperidon is a pure dopaminantagonist. It accelerates gastric emptying but has less effect on bowel motility.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2190745",
                    "offsetInBeginSection": 1092,
                    "offsetInEndSection": 1267,
                    "text": "Domperidone, which has also been shown to stimulate gastric motility and to possess antiemetic properties, improves symptoms in patients suffering from diabetic gastroparesis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3949445",
                    "offsetInBeginSection": 435,
                    "offsetInEndSection": 555,
                    "text": "It appears that the gastrokinetic properties of domperidone play a significant role in producing this anti-ulcer effect.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2588201",
                    "offsetInBeginSection": 312,
                    "offsetInEndSection": 448,
                    "text": "The observations with this drug in 68 women suffering from dyspepsia and in 94 cases of emesis of different etiology have been analysed.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3949445",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 163,
                    "text": "The effect of domperidone, a peripheral dopamine receptor antagonist, has been studied in the aspirin, phenylbutazone and reserpine induced gastric ulcers in rats.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2524845",
                    "offsetInBeginSection": 1001,
                    "offsetInEndSection": 1214,
                    "text": "Domperidone attenuated the renal response to AP, administered either as a bolus injection or a constant infusion, whereas domperidone significantly reduced renal response to APIII only following constant infusion.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3058373",
                    "offsetInBeginSection": 1492,
                    "offsetInEndSection": 1658,
                    "text": "Although the mechanism of action is not defined, it is concluded that domperidone is effective for the treatment of orthostatic hypotension in patients with diabetes.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8179003",
                    "offsetInBeginSection": 1320,
                    "offsetInEndSection": 1558,
                    "text": "Domperidone decreased the frequency of corporeal, pyloric, and duodenal contractions and deteriorated antropyloroduodenal coordination by decreasing the frequency of contractions propagating from the antrum or the pylorus to the duodenum.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19648670",
                    "offsetInBeginSection": 1229,
                    "offsetInEndSection": 1373,
                    "text": "Itopride, mosapride, domperidone, and clarithromycin can increase the amplitude and frequency of gastric and duodenal fast waves in the SD rats.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19648670",
                    "offsetInBeginSection": 743,
                    "offsetInEndSection": 861,
                    "text": "All prokinetic agents increased the amplitude and frequency of gastric and duodenal fast waves in the SD rats(P<0.05).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Explain the action of Domperidone.",
            "type": "summary",
            "id": "65f492bbc4010b4d78000011",
            "ideal_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/7736268",
                "http://www.ncbi.nlm.nih.gov/pubmed/34008907",
                "http://www.ncbi.nlm.nih.gov/pubmed/26304459",
                "http://www.ncbi.nlm.nih.gov/pubmed/2118248",
                "http://www.ncbi.nlm.nih.gov/pubmed/18156957",
                "http://www.ncbi.nlm.nih.gov/pubmed/25436022",
                "http://www.ncbi.nlm.nih.gov/pubmed/28368918",
                "http://www.ncbi.nlm.nih.gov/pubmed/18043144",
                "http://www.ncbi.nlm.nih.gov/pubmed/26866711",
                "http://www.ncbi.nlm.nih.gov/pubmed/10117163"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7736268",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 86,
                    "text": "Capnography is the measurement of carbon dioxide (CO2) concentration in a gas mixture.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34008907",
                    "offsetInBeginSection": 216,
                    "offsetInEndSection": 452,
                    "text": "Capnography is the non-invasive measurement of a sample of the exhaled carbon dioxide which has multiple clinical uses including as a method to confirm placement of a tracheal tube and/or to assess ventilation, perfusion and metabolism.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26304459",
                    "offsetInBeginSection": 1306,
                    "offsetInEndSection": 1358,
                    "text": "Delivery room EtCO2 monitoring is feasible and safe.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26304459",
                    "offsetInBeginSection": 1359,
                    "offsetInEndSection": 1477,
                    "text": "EtCO2 values obtained after birth reflect the establishment of functional residual capacity and effective ventilation.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2118248",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 155,
                    "text": "End-tidal carbon dioxide (ETCO2) monitoring is an effective tool to continuously assess the adequacy of ventilation in critically ill infants and children.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18156957",
                    "offsetInBeginSection": 277,
                    "offsetInEndSection": 518,
                    "text": "Capnography, a noninvasive monitoring technique designed to measure expired carbon dioxide (CO2) levels, has been used previously to identify respiratory placement of nasogastric tubes in adults; however, its use in children is understudied.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25436022",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 235,
                    "text": "Capnography provides a continuous, non-invasive monitoring of the CO2 to assess adequacy of ventilation and provide added safety features in mechanically ventilated patients by allowing for quick identification of unplanned extubation.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28368918",
                    "offsetInBeginSection": 237,
                    "offsetInEndSection": 359,
                    "text": "End-tidal carbon dioxide (EtCo2) monitoring provides immediate feedback of effective breathing during procedural sedation.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18043144",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 182,
                    "text": "We evaluated accuracy of end-tidal carbon dioxide tension (PETco2) monitoring and measured the effect of temperature correction of blood gas values in children after cardiac surgery.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26866711",
                    "offsetInBeginSection": 1156,
                    "offsetInEndSection": 1347,
                    "text": "There was a significant correlation between ETCO2 and PaCO2 (R = 0.7, p < 0.001), between PaCO2 and carotid flow (R = 0.52, p < 0.001) and between ETCO2 and carotid flow (R = 0.5, p < 0.001).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What does capnography measure?",
            "type": "factoid",
            "id": "65f38059c4010b4d7800000e",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/25518392",
                "http://www.ncbi.nlm.nih.gov/pubmed/24463630",
                "http://www.ncbi.nlm.nih.gov/pubmed/27006700",
                "http://www.ncbi.nlm.nih.gov/pubmed/32564333",
                "http://www.ncbi.nlm.nih.gov/pubmed/32169556",
                "http://www.ncbi.nlm.nih.gov/pubmed/37217309",
                "http://www.ncbi.nlm.nih.gov/pubmed/22926165",
                "http://www.ncbi.nlm.nih.gov/pubmed/31256279",
                "http://www.ncbi.nlm.nih.gov/pubmed/34310364",
                "http://www.ncbi.nlm.nih.gov/pubmed/31677060"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25518392",
                    "offsetInBeginSection": 552,
                    "offsetInEndSection": 657,
                    "text": "Fingolimod is teratogenic in rats. There is limited information on the safety of fingolimod in pregnancy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24463630",
                    "offsetInBeginSection": 1415,
                    "offsetInEndSection": 1620,
                    "text": "Given the known risks of teratogenicity in animals and the present data, women of childbearing potential should use effective contraception during fingolimod therapy and for 2 months after discontinuation.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27006700",
                    "offsetInBeginSection": 1295,
                    "offsetInEndSection": 1558,
                    "text": "A summary of the adverse events of interest that are associated with fingolimod treatment and associated label guidelines are also considered, which include cardiac effects following first-dose administration, infections, lymphopenia, macular edema and pregnancy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32564333",
                    "offsetInBeginSection": 1080,
                    "offsetInEndSection": 1306,
                    "text": "If a patient becomes pregnant while taking fingolimod, and requires continued DMD treatment, a switch to interferon  or natalizumab after a variable washout period may be prescribed, depending on the level of disease activity.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32169556",
                    "offsetInBeginSection": 387,
                    "offsetInEndSection": 604,
                    "text": "The aim of PRIM was to enhance the process of pregnancy data collection and improve data quality, and in particular to enable estimation of the proportion of major congenital malformation and other pregnancy outcomes.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24463630",
                    "offsetInBeginSection": 998,
                    "offsetInEndSection": 1149,
                    "text": "There were 5 cases (7.6%; 95% confidence interval 3%-17%) of abnormal fetal development in the 66 pregnancies that had in utero exposure to fingolimod.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37217309",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 108,
                    "text": "Discontinuation of fingolimod 2 months before pregnancy is recommended to minimize potential teratogenicity.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22926165",
                    "offsetInBeginSection": 636,
                    "offsetInEndSection": 770,
                    "text": "Conception should be discouraged for patients on fingolimod, because of the limited information available on human pregnancy outcomes.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31256279",
                    "offsetInBeginSection": 895,
                    "offsetInEndSection": 998,
                    "text": "During pregnancy, patients on natalizumab or fingolimod before pregnancy had a higher rate of relapses.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34310364",
                    "offsetInBeginSection": 453,
                    "offsetInEndSection": 669,
                    "text": "Drugs with a known potential of teratogenicity such as fingolimod or teriflunomide should be avoided and recommended wash-out times for medications such as cladribine, alemtuzumab or ocrelizumab should be considered.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Can fingolimod be used during pregnancy?",
            "type": "yesno",
            "id": "65d12ae11930410b13000030",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [],
            "snippets": [],
            "body": "Is sectoral Heterochromia associated with Crohn's disease?",
            "type": "yesno",
            "id": "65cfd68a1930410b13000021",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [],
            "snippets": [],
            "body": "What is the mechanism of action of Peresolimab?",
            "type": "summary",
            "id": "65d128f81930410b1300002d",
            "ideal_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23085895",
                "http://www.ncbi.nlm.nih.gov/pubmed/24657840"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23085895",
                    "offsetInBeginSection": 1604,
                    "offsetInEndSection": 1698,
                    "text": "EoE can be distinguished from GERD using a scoring system of clinical and endoscopic features.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23085895",
                    "offsetInBeginSection": 286,
                    "offsetInEndSection": 440,
                    "text": "Identifying clinical and endoscopic characteristics that distinguish EoE could provide a more comprehensive diagnostic strategy than the present criteria.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24657840",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 160,
                    "text": "Histologic analysis is used to distinguish patients with proton pump inhibitor-responsive eosinophilia (PPI-REE) from those with eosinophilic esophagitis (EoE).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24657840",
                    "offsetInBeginSection": 1603,
                    "offsetInEndSection": 1742,
                    "text": "The integrity of the esophageal mucosa is impaired in patients with EoE and PPI-REE, allowing transepithelial transport of small molecules.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24657840",
                    "offsetInBeginSection": 1743,
                    "offsetInEndSection": 1844,
                    "text": "PPI therapy partially restores mucosal integrity in patients with PPI-REE, but not in those with EoE.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Explain the difference between eosinophilic esophagitis and reflux-induced esophagitis.",
            "type": "summary",
            "id": "65f1d021c4010b4d78000004",
            "ideal_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/33492475",
                "http://www.ncbi.nlm.nih.gov/pubmed/23692043",
                "http://www.ncbi.nlm.nih.gov/pubmed/29682541",
                "http://www.ncbi.nlm.nih.gov/pubmed/12627249",
                "http://www.ncbi.nlm.nih.gov/pubmed/12755508",
                "http://www.ncbi.nlm.nih.gov/pubmed/26246230",
                "http://www.ncbi.nlm.nih.gov/pubmed/29431910",
                "http://www.ncbi.nlm.nih.gov/pubmed/30334997",
                "http://www.ncbi.nlm.nih.gov/pubmed/6596696",
                "http://www.ncbi.nlm.nih.gov/pubmed/21912940"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33492475",
                    "offsetInBeginSection": 1595,
                    "offsetInEndSection": 1849,
                    "text": "Lipectomy and liposuction are considered to be the most effective treatment methods for Madelung disease; however, choice of surgery should be based on comprehensive consideration of the disease, such as severity, mass location, and patient expectations.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23692043",
                    "offsetInBeginSection": 414,
                    "offsetInEndSection": 524,
                    "text": "The treatment of choice is lipectomy for severe cases and liposuction for less extensive accumulations of fat.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29682541",
                    "offsetInBeginSection": 521,
                    "offsetInEndSection": 673,
                    "text": "Lipectomy was performed in most cases and achieved more complete removal and better control of iatrogenic lesions of nearby structures than liposuction.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12627249",
                    "offsetInBeginSection": 687,
                    "offsetInEndSection": 854,
                    "text": "According to our experience, combined lipectomy and liposuction represents a successful procedure in treating benign symmetric lipomatosis in the head and neck region.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12755508",
                    "offsetInBeginSection": 852,
                    "offsetInEndSection": 999,
                    "text": "We think that combined lipectomy and liposuction is a successful procedure for treating benign symmetrical lipomatosis in the head and neck region.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12627249",
                    "offsetInBeginSection": 273,
                    "offsetInEndSection": 395,
                    "text": "Combined lipectomy and liposuction were performed in all patients, with liposuction being carried out in a second session.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12755508",
                    "offsetInBeginSection": 447,
                    "offsetInEndSection": 558,
                    "text": "Combined lipectomy and liposuction were done for all patients, with liposuction being done at a second session.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29682541",
                    "offsetInBeginSection": 236,
                    "offsetInEndSection": 290,
                    "text": "Surgical treatments include lipectomy and liposuction.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26246230",
                    "offsetInBeginSection": 156,
                    "offsetInEndSection": 269,
                    "text": "The only effective treatment is by surgical intervention; however, there is no consensus in the optimal approach.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29431910",
                    "offsetInBeginSection": 810,
                    "offsetInEndSection": 901,
                    "text": "Effective drug therapies are not known, but surgical procedures can alleviate the symptoms.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "List the most effective treatment methods for Madelung disease.",
            "type": "list",
            "id": "65f377d5c4010b4d78000009",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/26554731",
                "http://www.ncbi.nlm.nih.gov/pubmed/36919385",
                "http://www.ncbi.nlm.nih.gov/pubmed/23391351",
                "http://www.ncbi.nlm.nih.gov/pubmed/29517117",
                "http://www.ncbi.nlm.nih.gov/pubmed/38006748",
                "http://www.ncbi.nlm.nih.gov/pubmed/25553242",
                "http://www.ncbi.nlm.nih.gov/pubmed/25167164",
                "http://www.ncbi.nlm.nih.gov/pubmed/24922093",
                "http://www.ncbi.nlm.nih.gov/pubmed/21431558",
                "http://www.ncbi.nlm.nih.gov/pubmed/20003922"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26554731",
                    "offsetInBeginSection": 308,
                    "offsetInEndSection": 682,
                    "text": "We also present the recommendations of the Quebec Immunization Committee (CIQ) in this regard, which are: to provide targeted vaccination for MSM up to 26 years of age and in-school vaccination of preadolescent boys since this is the best approach to take to have a real impact on the burden related to HPV in the MSM population and to provide direct protection for all men.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36919385",
                    "offsetInBeginSection": 131,
                    "offsetInEndSection": 404,
                    "text": "The Advisory Committee on Immunization Practices did not recommend catch-up vaccination of adults aged 27-45 years, but recognized that some adults who were not previously vaccinated may be at risk for new HPV infection and might benefit from vaccination in this age range.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23391351",
                    "offsetInBeginSection": 2358,
                    "offsetInEndSection": 2587,
                    "text": "Accordingly, for prevention purposes and social fairness and equality, as both sexes are affected by the disease, the vaccination of 12-year-old males against HPV should be recommended in order to guaranty protection to everyone.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29517117",
                    "offsetInBeginSection": 232,
                    "offsetInEndSection": 487,
                    "text": "Even though a fall in cervical cancer rates has been reported worldwide, the subsequent rise in HPV-associated head and neck cancers among men and women have been reported from developed countries, necessitating the vaccination of adolescent boys as well.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38006748",
                    "offsetInBeginSection": 833,
                    "offsetInEndSection": 945,
                    "text": "It has also been suggested that vaccinating both men and women is more beneficial than vaccinating only females.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38006748",
                    "offsetInBeginSection": 1110,
                    "offsetInEndSection": 1267,
                    "text": "Well-coordinated vaccination strategy with focus on adolescent girls and if possible, boys can lead to dramatic impact on disease reduction around the world.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25553242",
                    "offsetInBeginSection": 918,
                    "offsetInEndSection": 1195,
                    "text": "Extension of immunization offer to young women and to adolescent male subjects has become an important additional opportunity for several countries, with a special focus needed on homosexual men with HIV infection who are at particularly increased risk of HPV-related diseases.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25167164",
                    "offsetInBeginSection": 1179,
                    "offsetInEndSection": 1322,
                    "text": "Vaccination also is recommended for females aged 13 through 26 years and for males aged 13 through 21 years who were not vaccinated previously.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24922093",
                    "offsetInBeginSection": 879,
                    "offsetInEndSection": 956,
                    "text": "A total of 489 (81.0%) would approve HPV vaccine for their teenage daughters.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21431558",
                    "offsetInBeginSection": 309,
                    "offsetInEndSection": 477,
                    "text": "Current intervention policy targets adolescent females for vaccination; however, the expansion of suggested guidelines may extend to other age groups and males as well.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Should men be immunized against Human Papilloma Virus?",
            "type": "summary",
            "id": "65f8611dc4010b4d78000055",
            "ideal_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/36720088",
                "http://www.ncbi.nlm.nih.gov/pubmed/38002722",
                "http://www.ncbi.nlm.nih.gov/pubmed/34100574",
                "http://www.ncbi.nlm.nih.gov/pubmed/21080791",
                "http://www.ncbi.nlm.nih.gov/pubmed/20569066",
                "http://www.ncbi.nlm.nih.gov/pubmed/24815101",
                "http://www.ncbi.nlm.nih.gov/pubmed/39826",
                "http://www.ncbi.nlm.nih.gov/pubmed/6759029",
                "http://www.ncbi.nlm.nih.gov/pubmed/23560561",
                "http://www.ncbi.nlm.nih.gov/pubmed/16354890"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36720088",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 157,
                    "text": "Breakthrough bleeding is a side effect of progesterone-only pills (POPs) in 40% of women, and is reduced to 10% with combined hormonal contraceptives (CHCs).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38002722",
                    "offsetInBeginSection": 183,
                    "offsetInEndSection": 304,
                    "text": "POPs are often associated with breakthrough bleeding (BTB), and irregular spotting is often a reason for their cessation.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34100574",
                    "offsetInBeginSection": 1025,
                    "offsetInEndSection": 1099,
                    "text": "Oligomenorrhea, spotting and headache were the three leading side-effects.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21080791",
                    "offsetInBeginSection": 800,
                    "offsetInEndSection": 884,
                    "text": "The most commonly reported complaints in women using all POPs are bleeding problems.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20569066",
                    "offsetInBeginSection": 1019,
                    "offsetInEndSection": 1194,
                    "text": "Progestogen-only pills are associated with a more irregular bleeding pattern than contraceptive pills containing oestrogens, especially during the first few months of therapy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24815101",
                    "offsetInBeginSection": 1004,
                    "offsetInEndSection": 1114,
                    "text": "Nausea was most frequent among COC users, dysmenorrhea among IUD users and acne and hirsutism among POP users.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39826",
                    "offsetInBeginSection": 635,
                    "offsetInEndSection": 741,
                    "text": "The only associated disadvantage is a tendency to more spotting and breakthrough bleeding in early cycles.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20569066",
                    "offsetInBeginSection": 721,
                    "offsetInEndSection": 940,
                    "text": "Progestogen-only pills have the potential to abolish many of the common adverse effects associated with oestrogen plus progestogen oral contraceptives and can be used to treat various menstrual cycle-dependent problems.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36720088",
                    "offsetInBeginSection": 248,
                    "offsetInEndSection": 409,
                    "text": "As breakthrough bleeding is responsible for a quarter of women stopping the pill, it is vital to realize that CHC is an alternative to POP-even during lactation.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/6759029",
                    "offsetInBeginSection": 284,
                    "offsetInEndSection": 429,
                    "text": "The benefits and disadvantages have been carefully evaluated and recommendations made for the more widespread use of progestogen-only mini-pills.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What are common side effects of the progesterone-only pill (POP)?",
            "type": "list",
            "id": "65f847c5c4010b4d78000046",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/36356934"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36356934",
                    "offsetInBeginSection": 770,
                    "offsetInEndSection": 977,
                    "text": "Levels of Ebola-related knowledge by community members varied widely. A large proportion of the Ebola-affected populations were not aware of modes of transmission and half were unaware of signs and symptoms.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What are the transmission mechanisms of the human Ebola infection?",
            "type": "list",
            "id": "65f84535c4010b4d78000044",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/34795410",
                "http://www.ncbi.nlm.nih.gov/pubmed/37190303",
                "http://www.ncbi.nlm.nih.gov/pubmed/35412531",
                "http://www.ncbi.nlm.nih.gov/pubmed/37627169"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34795410",
                    "offsetInBeginSection": 666,
                    "offsetInEndSection": 889,
                    "text": "ASP2453 potently and selectively inhibited KRAS G12C-mediated growth, KRAS activation and downstream signalling in vitro and in vivo, and improved the anti-tumour effects of targeted agents and immune checkpoint inhibitors.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34795410",
                    "offsetInBeginSection": 899,
                    "offsetInEndSection": 1071,
                    "text": "ASP2453 had more rapid binding kinetics to KRAS G12C protein and showed more potent inhibitory effects on KRAS activation and cell proliferation after washout than AMG 510.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37190303",
                    "offsetInBeginSection": 329,
                    "offsetInEndSection": 503,
                    "text": "Their foremost mechanism of action utilizes the Switch II binding pocket and Cys12 residue of GDP-bound KRAS proteins in G12C mutants, confining them to their inactive state.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35412531",
                    "offsetInBeginSection": 374,
                    "offsetInEndSection": 565,
                    "text": "In this article, we review the mechanism of action of KRAS G12C inhibitors and the latest clinical trials with sotorasib to provide a comprehensive understanding of its efficacy and toxicity.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37190303",
                    "offsetInBeginSection": 504,
                    "offsetInEndSection": 689,
                    "text": "Sotorasib and Adagrasib, both FDA-approved for the treatment of non-small cell lung cancer (NSCLC), have been pivotal in paving the way for KRAS G12C inhibitors in the clinical setting.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37627169",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 150,
                    "text": "RAS proteins are key regulators of cell signalling and control different cell functions including cell proliferation, differentiation, and cell death.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is the mechanisms of action of Sotorasib?",
            "type": "summary",
            "id": "65ce88be1930410b13000002",
            "ideal_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/35968245",
                "http://www.ncbi.nlm.nih.gov/pubmed/24163697",
                "http://www.ncbi.nlm.nih.gov/pubmed/24401287",
                "http://www.ncbi.nlm.nih.gov/pubmed/26664240",
                "http://www.ncbi.nlm.nih.gov/pubmed/29564309",
                "http://www.ncbi.nlm.nih.gov/pubmed/36989026",
                "http://www.ncbi.nlm.nih.gov/pubmed/10023416",
                "http://www.ncbi.nlm.nih.gov/pubmed/33388011",
                "http://www.ncbi.nlm.nih.gov/pubmed/32307942",
                "http://www.ncbi.nlm.nih.gov/pubmed/37829270"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35968245",
                    "offsetInBeginSection": 174,
                    "offsetInEndSection": 427,
                    "text": "Symptomatic uterine fibroids present with menstrual problems, anemia, infertility, miscarriages, an enlarged abdomen, pressure symptoms involving the bladder and bowels (such as frequent urination or constipation), and sometimes coital-related problems.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24163697",
                    "offsetInBeginSection": 136,
                    "offsetInEndSection": 392,
                    "text": "Clinically, they present with a variety of symptoms: excessive menstrual bleeding, dysmenorrhoea and intermenstrual bleeding, chronic pelvic pain, and pressure symptoms such as a sensation of bloatedness, increased urinary frequency, and bowel disturbance.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24401287",
                    "offsetInBeginSection": 287,
                    "offsetInEndSection": 496,
                    "text": "Symptomatic tumors can cause excessive uterine bleeding, bladder dysfunction and pelvic pain, as well as associated reproductive disorders such as infertility, miscarriage and other adverse pregnancy outcomes.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26664240",
                    "offsetInBeginSection": 397,
                    "offsetInEndSection": 493,
                    "text": "Typical complaints include pain, pressure sensations, dysmenorrhea or abnormal uterine bleeding.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29564309",
                    "offsetInBeginSection": 111,
                    "offsetInEndSection": 300,
                    "text": "Heavy or prolonged menstrual bleeding, abnormal uterine bleeding, resultant anemia, pelvic pain, infertility, and/or recurrent pregnancy loss are generally associated with uterine fibroids.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36989026",
                    "offsetInBeginSection": 309,
                    "offsetInEndSection": 452,
                    "text": "Uterine fibroid symptoms include abnormal menstrual bleeding leading to anaemia, tiredness, chronic vaginal discharge, and pain during periods.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36989026",
                    "offsetInBeginSection": 453,
                    "offsetInEndSection": 624,
                    "text": "Other symptoms include protrusion of the abdomen, pain during intercourse, dysfunctions of bladder/bowel leading to urinary incontinence/retention, pain, and constipation.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10023416",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 100,
                    "text": "Uterine fibroids, or leiomyomas, are the most common tumours in women during the reproductive years.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33388011",
                    "offsetInBeginSection": 86,
                    "offsetInEndSection": 269,
                    "text": "Heavy menstrual bleeding with resultant anemia, dysmenorrhea, chronic pelvic pain, infertility, urinary symptoms and constipation are generally associated with uterine fibroids (UFs).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32307942",
                    "offsetInBeginSection": 823,
                    "offsetInEndSection": 946,
                    "text": "The most common clinical finding was increased mass size (15 patients, 24.6%), while 9 patients (14.8%) showed no symptoms.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What are the most common symptoms of fibroids?",
            "type": "list",
            "id": "65f84aa5c4010b4d78000047",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/35582449",
                "http://www.ncbi.nlm.nih.gov/pubmed/36198171",
                "http://www.ncbi.nlm.nih.gov/pubmed/36469155",
                "http://www.ncbi.nlm.nih.gov/pubmed/31988000",
                "http://www.ncbi.nlm.nih.gov/pubmed/34120433",
                "http://www.ncbi.nlm.nih.gov/pubmed/29912274",
                "http://www.ncbi.nlm.nih.gov/pubmed/30962732",
                "http://www.ncbi.nlm.nih.gov/pubmed/37525669",
                "http://www.ncbi.nlm.nih.gov/pubmed/36572992",
                "http://www.ncbi.nlm.nih.gov/pubmed/34713870"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35582449",
                    "offsetInBeginSection": 603,
                    "offsetInEndSection": 715,
                    "text": "Recently, two potent and selective RET TKIs, pralsetinib (BLU-667) and selpercatinib (LOXO-292), were developed.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36198171",
                    "offsetInBeginSection": 185,
                    "offsetInEndSection": 340,
                    "text": "Six inhibitors have been approved for the treatment of RET-driven cancers: vandetanib, cabozantinib, lenvatinib, sorafenib, selpercatinib, and pralsetinib.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36469155",
                    "offsetInBeginSection": 267,
                    "offsetInEndSection": 449,
                    "text": "Here, we describe a case of a sarcoma, associated with a RET::TRIM33-fusion gene with an exceptional response to a neoadjuvant therapy with the selective RET inhibitor selpercatinib.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31988000",
                    "offsetInBeginSection": 2012,
                    "offsetInEndSection": 2156,
                    "text": "RET G810 solvent front mutations represent the first described recurrent mechanism of resistance to selective RET inhibition with selpercatinib.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34120433",
                    "offsetInBeginSection": 656,
                    "offsetInEndSection": 720,
                    "text": "Targeted drugs for RET gene fusion have been constantly updated.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29912274",
                    "offsetInBeginSection": 302,
                    "offsetInEndSection": 436,
                    "text": "LOXO-292 is a selective RET inhibitor designed to inhibit diverse RET fusions, activating mutations and acquired resistance mutations.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30962732",
                    "offsetInBeginSection": 208,
                    "offsetInEndSection": 375,
                    "text": "The RET gene can undergo chromosomal rearrangements in 1%-2% of all NSCLC patients, involving various upstream fusion partners such as KIF5B, CCDC6, NCOA4, and TRIM33.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37525669",
                    "offsetInBeginSection": 356,
                    "offsetInEndSection": 550,
                    "text": "Recent advancements in targeted therapies have led to the development of ret proto-oncogene (RET) inhibitors, such as selpercatinib and pralsetinib, which have been approved for the treatment of",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36572992",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 151,
                    "text": "Selpercatinib and pralsetinib are new targeted therapies used to treat patients with non-small cell lung cancer (NSCLC) due to RET gene rearrangements.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34713870",
                    "offsetInBeginSection": 317,
                    "offsetInEndSection": 488,
                    "text": "In May 2020, the U.S. Food and Drug Administration (FDA) approved a novel specific RET inhibitor for use in some subtypes of lung and thyroid cancers with RET alterations.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is the target of Selpercatinib?",
            "type": "factoid",
            "id": "65cfa22b1930410b1300000c",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/33142709",
                "http://www.ncbi.nlm.nih.gov/pubmed/37537946"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33142709",
                    "offsetInBeginSection": 572,
                    "offsetInEndSection": 683,
                    "text": "Compared to cetuximab, GC1118 exerted comparable growth inhibitory effects on the GBM tumors in the PDX models.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33142709",
                    "offsetInBeginSection": 684,
                    "offsetInEndSection": 867,
                    "text": "We confirmed that GC1118 accumulated within the tumor by crossing the blood-brain barrier in in vivo specimens and observed the survival benefit in GC1118-treated intracranial models.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37537946",
                    "offsetInBeginSection": 1426,
                    "offsetInEndSection": 1680,
                    "text": "This study did not meet the primary endpoint (PFS6); however, we found that immune signatures were significantly upregulated in the tumors with regression upon GC1118 therapy, which signifies the potential of immune-mediated antitumor efficacy of GC1118.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Is GC1118 effective for glioblastoma?",
            "type": "yesno",
            "id": "65d131451930410b13000034",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/37965976"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37965976",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 161,
                    "text": "COACH syndrome is a rare autosomal recessive genetic disease characterized by liver fibrosis, which leads to severe complications related to portal hypertension.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Is COACH syndrome a rare autosomal recessive genetic disease characterized by liver fibrosis and related to portal hypertension.",
            "type": "yesno",
            "id": "65f70d71c4010b4d7800001e",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/16481501",
                "http://www.ncbi.nlm.nih.gov/pubmed/31174702",
                "http://www.ncbi.nlm.nih.gov/pubmed/32500983",
                "http://www.ncbi.nlm.nih.gov/pubmed/32173315",
                "http://www.ncbi.nlm.nih.gov/pubmed/32059686",
                "http://www.ncbi.nlm.nih.gov/pubmed/33406079",
                "http://www.ncbi.nlm.nih.gov/pubmed/28502643",
                "http://www.ncbi.nlm.nih.gov/pubmed/26458781",
                "http://www.ncbi.nlm.nih.gov/pubmed/33314733",
                "http://www.ncbi.nlm.nih.gov/pubmed/21824373"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16481501",
                    "offsetInBeginSection": 554,
                    "offsetInEndSection": 651,
                    "text": "Infection in nature is maintained and transmitted by ticks as the principal vector and reservoir.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31174702",
                    "offsetInBeginSection": 727,
                    "offsetInEndSection": 981,
                    "text": "The identified publications are 29 case series, two case reports, 21 cohort studies and 21 case-control studies. With regard to the sources of infection, 25 publications describing the transmission of C. burnetii from sheep to humans could be identified.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32500983",
                    "offsetInBeginSection": 130,
                    "offsetInEndSection": 204,
                    "text": "Ticks may act as a vector and transmit the pathogen to animals and humans.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32173315",
                    "offsetInBeginSection": 1155,
                    "offsetInEndSection": 1349,
                    "text": "However, five Hyalomma dromedarii, one H. impeltatum and one H. excavatum tick species were detected positive for Coxiella burnetii DNA by qPCR, with an overall prevalence rate of 11.66% (7/60).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32059686",
                    "offsetInBeginSection": 1210,
                    "offsetInEndSection": 1354,
                    "text": "Transmission from both tick species might occur by inhalation of feces containing high amounts of viable C. burnetii rather than via tick bites.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33406079",
                    "offsetInBeginSection": 160,
                    "offsetInEndSection": 244,
                    "text": "ticks are usually thought to act as vectors on the basis of early microscopy studies",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33406079",
                    "offsetInBeginSection": 441,
                    "offsetInEndSection": 563,
                    "text": "we re-evaluated the vector competence of the African soft tick Ornithodoros moubata for an avirulent strain of C. burnetii",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28502643",
                    "offsetInBeginSection": 1217,
                    "offsetInEndSection": 1410,
                    "text": "Our data suggest that zebus as well as Amblyomma and Boophilus ticks have to be considered as a natural reservoir or vector for C. burnetii, but the risk of cattle-to-human transmission is low.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26458781",
                    "offsetInBeginSection": 150,
                    "offsetInEndSection": 254,
                    "text": "Transmission is primarily but not exclusively airborne, and ticks are usually thought to act as vectors.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33314733",
                    "offsetInBeginSection": 88,
                    "offsetInEndSection": 214,
                    "text": "Its primary mode of transmission is by inhalation of aerosols originating from infected animals and contaminated environments.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is the vector for coxiella burnetii transmission?",
            "type": "factoid",
            "id": "65f039fdc4010b4d78000002",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27996283",
                "http://www.ncbi.nlm.nih.gov/pubmed/25640666",
                "http://www.ncbi.nlm.nih.gov/pubmed/27582486",
                "http://www.ncbi.nlm.nih.gov/pubmed/22427377",
                "http://www.ncbi.nlm.nih.gov/pubmed/35434379",
                "http://www.ncbi.nlm.nih.gov/pubmed/26530251",
                "http://www.ncbi.nlm.nih.gov/pubmed/24382238",
                "http://www.ncbi.nlm.nih.gov/pubmed/31974915",
                "http://www.ncbi.nlm.nih.gov/pubmed/26369677",
                "http://www.ncbi.nlm.nih.gov/pubmed/33865428"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27996283",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 143,
                    "text": "IL-35 is a novel cytokine suppressing the immune response through the expansion of regulatory T cells and suppression of Th17 cell development.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25640666",
                    "offsetInBeginSection": 65,
                    "offsetInEndSection": 188,
                    "text": "Interleukin-35 (IL35) can suppress T cell proliferation and elicit the development of inducible regulatory T cells (Tregs).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27582486",
                    "offsetInBeginSection": 615,
                    "offsetInEndSection": 697,
                    "text": "IL35 plays an important role in the development of autoimmune diseases and cancer.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27582486",
                    "offsetInBeginSection": 698,
                    "offsetInEndSection": 841,
                    "text": "IL35 is overexpressed in a variety of cancers and may exert its function both on antitumor immune responses as well as directly on tumor cells.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22427377",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 131,
                    "text": "Interleukin (IL)-35 is a newly identified inhibitory cytokine used by T regulatory cells to control T cell-driven immune responses.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35434379",
                    "offsetInBeginSection": 95,
                    "offsetInEndSection": 379,
                    "text": "IL-35 includes two subunits, p35 and Epstein-Barr virus-induced gene 3, and activates subsequent signaling pathways by binding to receptors to mediate signal transduction, thereby modulating the immunoregulatory functions of T cells, B cells, macrophages, and other immune cell types.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25640666",
                    "offsetInBeginSection": 404,
                    "offsetInEndSection": 666,
                    "text": "Plasma IL35 levels were found to be lower in ITP patients than in healthy controls, were positively correlated with platelet levels and the percentage of peripheral circulating Tregs, and negatively correlated with the levels of T helper-1 cells in ITP patients.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25640666",
                    "offsetInBeginSection": 1057,
                    "offsetInEndSection": 1197,
                    "text": "IL35 appears to contribute to the loss of immunological self-tolerance in ITP patients by modulating T cells and immunoregulatory cytokines.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26530251",
                    "offsetInBeginSection": 821,
                    "offsetInEndSection": 953,
                    "text": "Among the cytokines, interleukin (IL)-35 is the one most recently discovered that suppresses inflammatory responses of immune cells.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27582486",
                    "offsetInBeginSection": 125,
                    "offsetInEndSection": 192,
                    "text": "IL35 has recently emerged as a novel regulator of immune responses.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is IL-35?",
            "type": "summary",
            "id": "65f5a319c4010b4d78000016",
            "ideal_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/37252346",
                "http://www.ncbi.nlm.nih.gov/pubmed/37904424",
                "http://www.ncbi.nlm.nih.gov/pubmed/36703601",
                "http://www.ncbi.nlm.nih.gov/pubmed/34991982",
                "http://www.ncbi.nlm.nih.gov/pubmed/36462104",
                "http://www.ncbi.nlm.nih.gov/pubmed/38031661"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37252346",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 210,
                    "text": "The advancement of nirmatrelvir, the active ingredient in Paxlovid, from discovery to emergency use authorization was achieved in just 17 months, requiring an unprecedented rate of chemical process development.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37904424",
                    "offsetInBeginSection": 844,
                    "offsetInEndSection": 1023,
                    "text": "The therapeutic approach involved a 5-day regimen of nirmatrelvir/ritonavir at a dosage of 300/100 mg administered twice daily, along with a daily dosage of 6 mg of dexamethasone.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36703601",
                    "offsetInBeginSection": 580,
                    "offsetInEndSection": 700,
                    "text": "The anti-COVID drugs explored via other approaches include nirmatrelvir (used in combination with ritonavir as Paxlovid)",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34991982",
                    "offsetInBeginSection": 768,
                    "offsetInEndSection": 869,
                    "text": "the novel Pfizer agent PAXLOVIDTM (PF-07321332), an investigational COVID-19 oral antiviral candidate",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36462104",
                    "offsetInBeginSection": 877,
                    "offsetInEndSection": 1072,
                    "text": "Notably, monoclonal antibodies have shown beneficial effects in the early stages of infection, while Paxlovid can significantly reduce hospitalization and mortality among non-vaccinated patients.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38031661",
                    "offsetInBeginSection": 593,
                    "offsetInEndSection": 659,
                    "text": "While a small-molecule drug (Paxlovid) received emergency approval",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What are active ingredients of Paxlovid?",
            "type": "list",
            "id": "65d136bc1930410b1300003c",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28453179",
                "http://www.ncbi.nlm.nih.gov/pubmed/34181963",
                "http://www.ncbi.nlm.nih.gov/pubmed/32423407",
                "http://www.ncbi.nlm.nih.gov/pubmed/33915947",
                "http://www.ncbi.nlm.nih.gov/pubmed/33375705",
                "http://www.ncbi.nlm.nih.gov/pubmed/35575755",
                "http://www.ncbi.nlm.nih.gov/pubmed/33915264",
                "http://www.ncbi.nlm.nih.gov/pubmed/35431543",
                "http://www.ncbi.nlm.nih.gov/pubmed/37632989",
                "http://www.ncbi.nlm.nih.gov/pubmed/36409624"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28453179",
                    "offsetInBeginSection": 612,
                    "offsetInEndSection": 814,
                    "text": "We propose a novel plot, the albatross plot, which requires only a 1-sided P value and a total sample size from each study (or equivalently a 2-sided P value, direction of effect and total sample size).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28453179",
                    "offsetInBeginSection": 815,
                    "offsetInEndSection": 955,
                    "text": "The plot allows an approximate examination of underlying effect sizes and the potential to identify sources of heterogeneity across studies.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34181963",
                    "offsetInBeginSection": 603,
                    "offsetInEndSection": 730,
                    "text": "albatross plots portrayed estimated effect sizes (standardized regression coefficients (s)), which were summarized in boxplots.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32423407",
                    "offsetInBeginSection": 746,
                    "offsetInEndSection": 963,
                    "text": "For interpretation of the results across studies, we produced albatross plots for all studies combined and by age-groups, sex of the parents, sex of the child, methodology of assessment of parental PA, and type of PA.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32423407",
                    "offsetInBeginSection": 1285,
                    "offsetInEndSection": 1432,
                    "text": "The albatross plot for all studies combined showed that the clear majority of studies observed a positive relationship between parent and child PA.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33915947",
                    "offsetInBeginSection": 548,
                    "offsetInEndSection": 623,
                    "text": "The direction of the effect is also shown in the form of an albatross plot.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33375705",
                    "offsetInBeginSection": 712,
                    "offsetInEndSection": 785,
                    "text": "Albatross plot was also used to present the direction of effect observed.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35575755",
                    "offsetInBeginSection": 638,
                    "offsetInEndSection": 687,
                    "text": "Albatross plots were used to synthesise the data.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35575755",
                    "offsetInBeginSection": 899,
                    "offsetInEndSection": 967,
                    "text": "These outcome measures were utilised to develop two Albatross plots.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33915264",
                    "offsetInBeginSection": 639,
                    "offsetInEndSection": 737,
                    "text": "Synthesis of included articles was performed using effect direction heat maps and albatross plots.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is an Albatross plot used for?",
            "type": "factoid",
            "id": "65f37997c4010b4d7800000b",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/12583828",
                "http://www.ncbi.nlm.nih.gov/pubmed/864277",
                "http://www.ncbi.nlm.nih.gov/pubmed/26547381",
                "http://www.ncbi.nlm.nih.gov/pubmed/3178237",
                "http://www.ncbi.nlm.nih.gov/pubmed/17534933",
                "http://www.ncbi.nlm.nih.gov/pubmed/24348319",
                "http://www.ncbi.nlm.nih.gov/pubmed/31890337",
                "http://www.ncbi.nlm.nih.gov/pubmed/24704904",
                "http://www.ncbi.nlm.nih.gov/pubmed/19337845",
                "http://www.ncbi.nlm.nih.gov/pubmed/36532750"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12583828",
                    "offsetInBeginSection": 300,
                    "offsetInEndSection": 502,
                    "text": "Methotrexate inhibits dihydrofolate reductase, which leads to accumulation of polyglutamated folates, causing further inhibition of thymidylate synthase and glycinamide ribonucleotide formyltransferase.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/864277",
                    "offsetInBeginSection": 421,
                    "offsetInEndSection": 537,
                    "text": "Of the 24 compounds studied, methotrexate (MTX) was the most potent inhibitor of rat skin DHFR (I50=8.6 X 10(-9) M).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26547381",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 172,
                    "text": "Methotrexate (MTX), a folate antagonist which blocks de novo nucleotide biosynthesis and DNA replication, is an anchor drug in acute lymphoblastic leukemia (ALL) treatment.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3178237",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 110,
                    "text": "Methotrexate (MTX), a folic acid antagonist, is among the most active known drugs for clinical cancer therapy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17534933",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 106,
                    "text": "The folate inhibitor methotrexate (MTX) is an important component of osteosarcoma (OS) treatment regimens.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24348319",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 126,
                    "text": "Methotrexate (MTX), a folic acid antagonist, is widely used in the treatment of neoplasms, psoriasis and rheumatoid arthritis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31890337",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 170,
                    "text": "Methotrexate (MTX) is a folate antagonist drug used for several diseases, such as cancers, various malignancies, rheumatoid arthritis (RA) and inflammatory bowel disease.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24704904",
                    "offsetInBeginSection": 69,
                    "offsetInEndSection": 265,
                    "text": "Methotrexate (MTX) is a folic acid antagonist used in high doses as antimetabolite in anti-cancer treatment as well as in low doses for the treatment of rheumatoid arthritis and adults' psoriasis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19337845",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 90,
                    "text": "Antifolates, such as methotrexate (MTX), are the treatment of choice for numerous cancers.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36532750",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 195,
                    "text": "Methotrexate (MTX) is a folic acid antagonist, the mechanism of action is to inhibit DNA synthesis, repair and cell proliferation by decreasing the activities of several folate-dependent enzymes.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Methotrexate is an antifolate medication.",
            "type": "yesno",
            "id": "65f82fe1c4010b4d7800003f",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/29411996",
                "http://www.ncbi.nlm.nih.gov/pubmed/15514399",
                "http://www.ncbi.nlm.nih.gov/pubmed/31456039",
                "http://www.ncbi.nlm.nih.gov/pubmed/18434919",
                "http://www.ncbi.nlm.nih.gov/pubmed/24761500",
                "http://www.ncbi.nlm.nih.gov/pubmed/30007773",
                "http://www.ncbi.nlm.nih.gov/pubmed/9022648",
                "http://www.ncbi.nlm.nih.gov/pubmed/21969769",
                "http://www.ncbi.nlm.nih.gov/pubmed/27989927",
                "http://www.ncbi.nlm.nih.gov/pubmed/15167087"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29411996",
                    "offsetInBeginSection": 949,
                    "offsetInEndSection": 1131,
                    "text": "Low energy, excessive worry, excessive guilt, anhedonia, social withdrawal, and sadness or depressed mood were each associated with a significantly higher likelihood of onset of MDD.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15514399",
                    "offsetInBeginSection": 914,
                    "offsetInEndSection": 1255,
                    "text": "The anhedonic depressed subgroup identified was characterized by greater depression severity, alterations in stress cortisol reactivity, increased family history of major depressive disorder, and increased frequency of psychomotor retardation as well as other melancholic symptoms, such as a lack of brightening in response to joyful events.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31456039",
                    "offsetInBeginSection": 733,
                    "offsetInEndSection": 1029,
                    "text": "Anxious depressed youth were more likely to suffer recurrent depressive episodes, showed higher depression severity and a unique pattern of depressive symptoms characterized by more severe sleep problems, more somatic complaints, more severely depressed mood and more frequent suicidal ideations.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18434919",
                    "offsetInBeginSection": 1036,
                    "offsetInEndSection": 1186,
                    "text": "Mothers with higher levels of depressive symptoms had children with higher levels of depression severity at baseline and over the course of treatment.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18434919",
                    "offsetInBeginSection": 582,
                    "offsetInEndSection": 696,
                    "text": "Thirty percent of mothers had moderate to severe levels of depressive symptoms at the child's baseline assessment.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24761500",
                    "offsetInBeginSection": 178,
                    "offsetInEndSection": 260,
                    "text": "Clinical depression varies in the nature and intensity of its presenting symptoms.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24761500",
                    "offsetInBeginSection": 108,
                    "offsetInEndSection": 177,
                    "text": "Symptoms of depression may differ from those of the adult depression.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30007773",
                    "offsetInBeginSection": 1360,
                    "offsetInEndSection": 1550,
                    "text": "The CBCL anxiety/depression scale was useful in identifying children at high risk for the development of major depressive disorder and anxiety disorders at the 10-year prospective follow-up.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9022648",
                    "offsetInBeginSection": 513,
                    "offsetInEndSection": 609,
                    "text": "The predominant symptoms in young children were central nervous system depression and hypotonia.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21969769",
                    "offsetInBeginSection": 531,
                    "offsetInEndSection": 690,
                    "text": "Preschool depression is characterized by typical symptoms of depression such as anhedonia; changes in sleep, appetite, and activity level; and excessive guilt.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Which symptoms could indicate depression in young children?",
            "type": "list",
            "id": "65f86f62c4010b4d7800005c",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [],
            "snippets": [],
            "body": "What is the mechanism of action of sparsentan?",
            "type": "summary",
            "id": "65cebf371930410b13000004",
            "ideal_answer": ""
        },
        {
            "documents": [],
            "snippets": [],
            "body": "Is it advisable to bring the fever down when it is supposedly meant to assist in the fight of disease?",
            "type": "summary",
            "id": "65f8418fc4010b4d78000041",
            "ideal_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28850647",
                "http://www.ncbi.nlm.nih.gov/pubmed/27514296"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28850647",
                    "offsetInBeginSection": 1007,
                    "offsetInEndSection": 1129,
                    "text": "Nurses should educate patients about these disorders and evidence-based treatments, including off-label use of naltrexone.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27514296",
                    "offsetInBeginSection": 139,
                    "offsetInEndSection": 405,
                    "text": "Although the risk of drug-induced extrapyramidal syndromes has been mitigated by the acceptance of less potent dopamine antagonists, expansive marketing and off-label use has increased the number of susceptible people who may be at risk for these neurologic effects.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What disorder is considered off label use for domperidone?",
            "type": "factoid",
            "id": "65f493cac4010b4d78000012",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/16573430",
                "http://www.ncbi.nlm.nih.gov/pubmed/1350318",
                "http://www.ncbi.nlm.nih.gov/pubmed/3516107",
                "http://www.ncbi.nlm.nih.gov/pubmed/16002027",
                "http://www.ncbi.nlm.nih.gov/pubmed/36415069",
                "http://www.ncbi.nlm.nih.gov/pubmed/10423599",
                "http://www.ncbi.nlm.nih.gov/pubmed/9282421",
                "http://www.ncbi.nlm.nih.gov/pubmed/7486378",
                "http://www.ncbi.nlm.nih.gov/pubmed/11564057",
                "http://www.ncbi.nlm.nih.gov/pubmed/10510137"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16573430",
                    "offsetInBeginSection": 338,
                    "offsetInEndSection": 522,
                    "text": "As with any overdose, the most important aspects in the management is the maintenance of the patient's airway, ventilation and circulation, while the toxin is metabolised and excreted.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1350318",
                    "offsetInBeginSection": 1479,
                    "offsetInEndSection": 1593,
                    "text": "Gastric lavage is used if the patient presents within one hour of ingestion and has clinical features of toxicity.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1350318",
                    "offsetInBeginSection": 1292,
                    "offsetInEndSection": 1478,
                    "text": "Most patients are managed with supportive care and, in the absence of contraindications, a single dose of activated charcoal if seen within four hours of ingestion of the poison or drug.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3516107",
                    "offsetInBeginSection": 117,
                    "offsetInEndSection": 228,
                    "text": "Activated charcoal can be used orally to prevent drug and poison absorption in cases of overdose and poisoning.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16002027",
                    "offsetInBeginSection": 1159,
                    "offsetInEndSection": 1416,
                    "text": "Efforts to equip drug users to manage overdoses effectively, including training in first aid and the provision of naloxone, and the reduction of police involvement at overdose events may have a substantial impact on overdose-related morbidity and mortality.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36415069",
                    "offsetInBeginSection": 610,
                    "offsetInEndSection": 734,
                    "text": "Supportive care, with particular attention to airway management, oxygenation, and circulation, is the mainstay of treatment.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36415069",
                    "offsetInBeginSection": 735,
                    "offsetInEndSection": 928,
                    "text": "Basic treatment principles include limiting the amount of toxin absorbed, enhancing the elimination of ingested toxin, and preventing the conversion of non-toxic compounds to toxic metabolites.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10423599",
                    "offsetInBeginSection": 190,
                    "offsetInEndSection": 297,
                    "text": "The clinician must be able to diagnose and treat the patient to prevent unnecessary morbidity or mortality.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10423599",
                    "offsetInBeginSection": 298,
                    "offsetInEndSection": 412,
                    "text": "Often the risk of treating drug overdose with an additional pharmacological agent outweighs the potential benefit.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9282421",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 185,
                    "text": "Each year about 100,000 people present to UK hospitals with deliberate self-harm, the most common form of which is poisoning with medicines or other pharmacologically active substances.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What should you do if you find an individual that you suspect has overdosed?",
            "type": "list",
            "id": "65f85df3c4010b4d78000051",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/37267792",
                "http://www.ncbi.nlm.nih.gov/pubmed/3404600",
                "http://www.ncbi.nlm.nih.gov/pubmed/32218425",
                "http://www.ncbi.nlm.nih.gov/pubmed/6308444",
                "http://www.ncbi.nlm.nih.gov/pubmed/21994137",
                "http://www.ncbi.nlm.nih.gov/pubmed/20011362",
                "http://www.ncbi.nlm.nih.gov/pubmed/30350534",
                "http://www.ncbi.nlm.nih.gov/pubmed/27780947",
                "http://www.ncbi.nlm.nih.gov/pubmed/7392128",
                "http://www.ncbi.nlm.nih.gov/pubmed/6765390"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37267792",
                    "offsetInBeginSection": 1468,
                    "offsetInEndSection": 1657,
                    "text": "Severe proctitis leading to large bowel obstruction is a possible presentation of syphilis, and a high degree of clinical suspicion is necessary to be able to accurately identify the cause.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3404600",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 306,
                    "text": "We analyzed the association of herpes simplex virus (HSV) infection and syphilis, the two most common causes of genital ulceration in homosexual men, with human immunodeficiency virus (HIV) infection in 200 men enrolled between 1983 and 1986 into a study evaluating the microbial causes of acute proctitis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32218425",
                    "offsetInBeginSection": 878,
                    "offsetInEndSection": 1007,
                    "text": "The commonest implicated pathogens are Neysseria gonorrhoeae, Chlamydia trachomatis, Herpes Simplex virus and Treponema pallidum.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/6308444",
                    "offsetInBeginSection": 655,
                    "offsetInEndSection": 856,
                    "text": "Neisseria gonorrhoeae, herpes simplex virus, Chlamydia trachomatis (non-lymphogranuloma venereum serotypes), and Treponema pallidum were associated with 80 per cent of cases with symptomatic proctitis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21994137",
                    "offsetInBeginSection": 342,
                    "offsetInEndSection": 474,
                    "text": "The most frequently reported pathogens include Neisseria gonorrhoeae, Chlamydia trachomatis, Treponema pallidum, and herpes simplex.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20011362",
                    "offsetInBeginSection": 519,
                    "offsetInEndSection": 636,
                    "text": "Common causative agents include Neisseria gonorrhoeae, Chlamydia trachomatis, Treponema pallidum, and herpes simplex.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20011362",
                    "offsetInBeginSection": 742,
                    "offsetInEndSection": 861,
                    "text": "The clinician must remember to keep these diseases in mind while formulating a differential for the cause of proctitis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21994137",
                    "offsetInBeginSection": 475,
                    "offsetInEndSection": 622,
                    "text": "Symptoms of infectious proctitis can include rectal blood and mucous discharge, anorectal pain, ulcers, and occasionally lymphadenopathy and fever.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30350534",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 80,
                    "text": "Rectal ulcerations are an uncommon presentation of a primary syphilis infection.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27780947",
                    "offsetInBeginSection": 154,
                    "offsetInEndSection": 231,
                    "text": "The endoscopic findings of rectal syphilis are proctitis, ulcers, and masses.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Can syphilis cause proctitis?",
            "type": "yesno",
            "id": "65cfd13f1930410b1300001d",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24576790",
                "http://www.ncbi.nlm.nih.gov/pubmed/35725830",
                "http://www.ncbi.nlm.nih.gov/pubmed/21424418",
                "http://www.ncbi.nlm.nih.gov/pubmed/21404630",
                "http://www.ncbi.nlm.nih.gov/pubmed/18827717",
                "http://www.ncbi.nlm.nih.gov/pubmed/9924841",
                "http://www.ncbi.nlm.nih.gov/pubmed/2577300",
                "http://www.ncbi.nlm.nih.gov/pubmed/21963369",
                "http://www.ncbi.nlm.nih.gov/pubmed/7795952",
                "http://www.ncbi.nlm.nih.gov/pubmed/11122979"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24576790",
                    "offsetInBeginSection": 850,
                    "offsetInEndSection": 929,
                    "text": "Neurotransmitters implicated in OCD include serotonin, dopamine, and glutamate.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35725830",
                    "offsetInBeginSection": 663,
                    "offsetInEndSection": 904,
                    "text": "On a molecular level, genetic variants and epigenetic variations in the serotonergic, dopaminergic and glutamatergic systems in particular seem to play a role in the pathogenesis of the disease and affect the corresponding neurotransmission.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21424418",
                    "offsetInBeginSection": 600,
                    "offsetInEndSection": 848,
                    "text": "Neurochemical studies have shown that OCD is linked to changes of the central modulatory transmitter system, especially, the serotonin and dopamine system, which probably contribute to a direct and indirect dysregulation in various neural networks.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21404630",
                    "offsetInBeginSection": 737,
                    "offsetInEndSection": 921,
                    "text": "Although much of the emphasis of pathophysiologic theories of OCD has been on serotonin, a growing body of evidence supports a role for dopaminergic neurotransmission in this disorder.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18827717",
                    "offsetInBeginSection": 491,
                    "offsetInEndSection": 585,
                    "text": "Genetic and neurochemical studies also implicate glutamate in the pathological finding of OCD.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9924841",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 174,
                    "text": "The serotonin (5-HT) neurotransmitter system has been implicated in the pathophysiology of several neuropsychiatric disorders, especially obsessive-compulsive disorder (OCD).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2577300",
                    "offsetInBeginSection": 1212,
                    "offsetInEndSection": 1508,
                    "text": "While studies of neurotransmitter function have primarily implicated dopaminergic dysfunction in TS and serotonergic function in OCD, other systems may be involved in each disorder, and neurotransmitter systems may be tightly linked, such that alterations of one system will affect other systems.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21963369",
                    "offsetInBeginSection": 543,
                    "offsetInEndSection": 732,
                    "text": "Recent evidence suggests that the ubiquitous excitatory neurotransmitter glutamate is dysregulated in OCD, and that this dysregulation may contribute to the pathophysiology of the disorder.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7795952",
                    "offsetInBeginSection": 103,
                    "offsetInEndSection": 208,
                    "text": "Its capacity to block serotonin reuptake appears to be essential to reducing the primary symptoms of OCD.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7795952",
                    "offsetInBeginSection": 854,
                    "offsetInEndSection": 936,
                    "text": "This variation suggests that other neurochemical systems may be implicated in OCD.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Which neurotransmitters are thought to play a role in obsessive compulsive disorder?",
            "type": "list",
            "id": "65f8721ec4010b4d7800005d",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27697312",
                "http://www.ncbi.nlm.nih.gov/pubmed/16155434",
                "http://www.ncbi.nlm.nih.gov/pubmed/25745635",
                "http://www.ncbi.nlm.nih.gov/pubmed/25557356",
                "http://www.ncbi.nlm.nih.gov/pubmed/31177576",
                "http://www.ncbi.nlm.nih.gov/pubmed/25542979",
                "http://www.ncbi.nlm.nih.gov/pubmed/23720161",
                "http://www.ncbi.nlm.nih.gov/pubmed/19882635",
                "http://www.ncbi.nlm.nih.gov/pubmed/16769963",
                "http://www.ncbi.nlm.nih.gov/pubmed/32505442"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27697312",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 378,
                    "text": "Adult and pediatric patients suffering from MuSK (muscle-specific kinase) -antibody positive myasthenia gravis exhibit similar features to individuals with acetylcholine receptor (AChR) antibodies, but they differ in several characteristics such as a predominant bulbar, respiratory and neck weakness, a generally worse disease severity and a tendency to develop muscle atrophy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16155434",
                    "offsetInBeginSection": 1315,
                    "offsetInEndSection": 1463,
                    "text": "MuSK antibodies define a form of myasthenia gravis that can be difficult to diagnose, can be life threatening and may require additional treatments.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25745635",
                    "offsetInBeginSection": 1436,
                    "offsetInEndSection": 1657,
                    "text": "B10 cells, a recently described rare regulatory B-cell subset that potently blocks Th1 and Th17 responses, were reduced, which suggests a potential mechanism for the breakdown in immune tolerance in patients with MuSK MG.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25557356",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 250,
                    "text": "Anti-muscle specific kinase antibody positive myasthenia gravis (MuSK MG) is often characterized by a relatively severe and progressive course, refractoriness to standard myasthenia gravis (MG) medications, and an increased risk of myasthenic crisis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31177576",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 237,
                    "text": "Muscle-specific tyrosine kinase (MuSK) autoantibody related myasthenia gravis is characterized by bulbar and respiratory manifestations, a poor response to anticholinergics, and a generally good response to plasma exchange and rituximab.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25745635",
                    "offsetInBeginSection": 1186,
                    "offsetInEndSection": 1312,
                    "text": "Increased BAFF levels have been described in other autoimmune diseases, including acetylcholine receptor antibody-positive MG.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16155434",
                    "offsetInBeginSection": 567,
                    "offsetInEndSection": 778,
                    "text": "MuSK antibodies are found in a variable proportion of AChR antibody negative myasthenia gravis patients who are often, but not exclusively, young adult females, with bulbar, neck, or respiratory muscle weakness.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27697312",
                    "offsetInBeginSection": 465,
                    "offsetInEndSection": 656,
                    "text": "We describe a girl with MuSK-antibody positive myasthenia gravis who developed a myopathy with severe generalized muscular weakness, muscle atrophy, and myopathic changes on electromyography.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27697312",
                    "offsetInBeginSection": 657,
                    "offsetInEndSection": 750,
                    "text": "This is the first published example of a generalized myopathic syndrome in myasthenia gravis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25542979",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 166,
                    "text": "Muscle-specific tyrosine kinase (MuSK) autoantibodies are the hallmark of a form of myasthenia gravis (MG) that can challenge the neurologist and the experimentalist.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Please summarize MuSK Antibody positive Myasthenia Gravis.",
            "type": "summary",
            "id": "65f70915c4010b4d7800001a",
            "ideal_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/25884045",
                "http://www.ncbi.nlm.nih.gov/pubmed/26827069",
                "http://www.ncbi.nlm.nih.gov/pubmed/22985897",
                "http://www.ncbi.nlm.nih.gov/pubmed/25073227",
                "http://www.ncbi.nlm.nih.gov/pubmed/28555210",
                "http://www.ncbi.nlm.nih.gov/pubmed/31109863",
                "http://www.ncbi.nlm.nih.gov/pubmed/37326685",
                "http://www.ncbi.nlm.nih.gov/pubmed/26893859",
                "http://www.ncbi.nlm.nih.gov/pubmed/30699493",
                "http://www.ncbi.nlm.nih.gov/pubmed/28535616"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25884045",
                    "offsetInBeginSection": 518,
                    "offsetInEndSection": 636,
                    "text": "The literature shows that Denosumab can cause ONJ associated with triggers such as microtraumas or dental extractions.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26827069",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 197,
                    "text": "Denosumab, an anti-resorptive agent, IgG2 monoclonal antibody for human Receptor activator of nuclear factor-kappa B ligand (RANKL), has been related to the occurrence of osteonecrosis of the jaws.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22985897",
                    "offsetInBeginSection": 421,
                    "offsetInEndSection": 590,
                    "text": "Denosumab, an osteoclast inhibitor with applications in orthopedics and oncology, causes ONJ at a rate comparable to that for intravenously administered bisphosphonates.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25884045",
                    "offsetInBeginSection": 927,
                    "offsetInEndSection": 1007,
                    "text": "Denosumab, Sunitinib or Bevacizumab are causal agents in the development of ONJ.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25073227",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 79,
                    "text": "Osteonecrosis of the jaw (ONJ) following bisphosphonate use is well documented.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25073227",
                    "offsetInBeginSection": 80,
                    "offsetInEndSection": 324,
                    "text": "However, to our knowledge, there are few cases reported on ONJ related to the use of other pharmaceutical agents, such as denosumab--a monoclonal antibody that is prescribed for the treatment of osteoporosis and is used as an anti-cancer agent.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28555210",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 151,
                    "text": "To report a case of osteonecrosis of the jaw (ONJ) occurring in an implant area possibly related to denosumab, a relatively new antiosteoporotic agent.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28555210",
                    "offsetInBeginSection": 807,
                    "offsetInEndSection": 1017,
                    "text": "A cumulative effect of denosumab is likely to be associated with a jaw osteonecrosis, which in this case was manageable using a surgical approach with no need to interrupt the appropriate drug treatment course.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31109863",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 160,
                    "text": "Antiresorptive agents such as bisphosphonates and denosumab, as well as angiogenesis inhibitors, may induce medication-related osteonecrosis of the jaw (MRONJ).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31109863",
                    "offsetInBeginSection": 1166,
                    "offsetInEndSection": 1259,
                    "text": "No reliable information about ONJ induced by denosumab and angiogenesis inhibitors was found.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Can denosumab cause jaw necrosis?",
            "type": "yesno",
            "id": "65d126d21930410b1300002c",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/30090133",
                "http://www.ncbi.nlm.nih.gov/pubmed/25062301",
                "http://www.ncbi.nlm.nih.gov/pubmed/22222434",
                "http://www.ncbi.nlm.nih.gov/pubmed/11441995",
                "http://www.ncbi.nlm.nih.gov/pubmed/28057596",
                "http://www.ncbi.nlm.nih.gov/pubmed/31073683",
                "http://www.ncbi.nlm.nih.gov/pubmed/36314835",
                "http://www.ncbi.nlm.nih.gov/pubmed/26994012",
                "http://www.ncbi.nlm.nih.gov/pubmed/15630948",
                "http://www.ncbi.nlm.nih.gov/pubmed/26754996"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30090133",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 96,
                    "text": "Ventriculoperitoneal (VP) shunting is the most common neurosurgical treatment for hydrocephalus.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25062301",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 87,
                    "text": "Ventriculoperitoneal (VP) shunt surgery is the most common treatment for hydrocephalus.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22222434",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 108,
                    "text": "Ventriculoperitoneal (VP) shunt surgery is the most common technique used in the treatment of hydrocephalus.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11441995",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 119,
                    "text": "Ventriculoperitoneal (VP) shunts are among the most frequently performed operations in the management of hydrocephalus.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28057596",
                    "offsetInBeginSection": 834,
                    "offsetInEndSection": 979,
                    "text": "Seventy-seven (74.7%) patients underwent ventriculoperitoneal (VP) shunting, whereas 24 (23.3%) underwent endoscopic third ventriculostomy (ETV).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31073683",
                    "offsetInBeginSection": 1140,
                    "offsetInEndSection": 1204,
                    "text": "The most common reason for revision in both groups was blockage.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36314835",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 195,
                    "text": "Hydrocephalus is a common adult neurosurgical condition typically requiring treatment with a cerebrospinal fluid (CSF) shunt, of which the ventriculoperitoneal (VP) shunt is the most common type.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26994012",
                    "offsetInBeginSection": 100,
                    "offsetInEndSection": 398,
                    "text": "Although ventriculoperitoneal shunts (VPSs) were previously used for treating this condition, they have recently been replaced by endoscopic third ventriculostomy (ETV), as the latter can avoid various complications caused by a VPS and can preserve physiological cerebrospinal fluid (CSF) dynamics.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15630948",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 90,
                    "text": "Ventriculoperitoneal (VP) shunts are the most common treatment modality for hydrocephalus.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26754996",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 194,
                    "text": "Endoscopic third ventriculostomy (ETV), wherein a stoma is created in the floor of the third ventricle, has now become the standard procedure for noncommunicating hydrocephalus across the world.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is the most common surgical treatment for hydrocephalus?",
            "type": "factoid",
            "id": "65f85ec7c4010b4d78000052",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/30476721",
                "http://www.ncbi.nlm.nih.gov/pubmed/37321200",
                "http://www.ncbi.nlm.nih.gov/pubmed/31697951",
                "http://www.ncbi.nlm.nih.gov/pubmed/32599143",
                "http://www.ncbi.nlm.nih.gov/pubmed/37327371",
                "http://www.ncbi.nlm.nih.gov/pubmed/37600520",
                "http://www.ncbi.nlm.nih.gov/pubmed/37923146",
                "http://www.ncbi.nlm.nih.gov/pubmed/35082916",
                "http://www.ncbi.nlm.nih.gov/pubmed/12579834",
                "http://www.ncbi.nlm.nih.gov/pubmed/35572137"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30476721",
                    "offsetInBeginSection": 228,
                    "offsetInEndSection": 327,
                    "text": "We found that melatonin reduced infarct area and suppressed neuron death during reperfusion stress.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37321200",
                    "offsetInBeginSection": 1435,
                    "offsetInEndSection": 1598,
                    "text": "Melatonin treatment following CI reduced the infarct area and induced the autophagic proteins Beclin-1, LC3, and p62 by inhibiting the apoptotic caspase-3 protein.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31697951",
                    "offsetInBeginSection": 1139,
                    "offsetInEndSection": 1289,
                    "text": "Our research proved that melatonin promoted SIRT3 expression after tMCAO and alleviated cerebral I/R injury by activating the SIRT3 signaling pathway.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32599143",
                    "offsetInBeginSection": 1256,
                    "offsetInEndSection": 1546,
                    "text": "Melatonin treatment significantly decreased infarct volume and cerebral apoptosis; mitigated endoplasmic reticulum stress and mitochondrial dysfunction; and inhibited CI/R injury-induced oxidative/nitrative stress and nuclear factor-B activation, which was eradicated in ROR-deficient mice.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37327371",
                    "offsetInBeginSection": 1648,
                    "offsetInEndSection": 1762,
                    "text": "Melatonin treatment is neuroprotective against CIRI in T1DM rats via anti-inflammatory and anti-apoptotic effects.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30476721",
                    "offsetInBeginSection": 934,
                    "offsetInEndSection": 1085,
                    "text": "Melatonin supplementation enhances OPA1-related mitochondrial fusion by activating the Yap-Hippo pathway, ultimately reducing brain reperfusion stress.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37600520",
                    "offsetInBeginSection": 882,
                    "offsetInEndSection": 1074,
                    "text": "Therefore, understanding the underlying intracellular and molecular mechanisms is crucial before investigating the neuroprotective effects of melatonin in cerebral ischemia-reperfusion injury.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37923146",
                    "offsetInBeginSection": 2394,
                    "offsetInEndSection": 2535,
                    "text": "Furthermore, the neuroprotective effect of Mel treatment is associated with its promotion of the microglia polarized to M2 type in CIRI rats.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35082916",
                    "offsetInBeginSection": 1234,
                    "offsetInEndSection": 1522,
                    "text": "In the MACO rat model, melatonin can effectively reduce Bax and Caspase-3 levels by modulating the JNK/FoxO3a/Bim pathway, inhibit neuronal apoptosis, and alleviate neurological deficits by reducing the release of proinflammatory mediators, with anti-inflammatory and antioxidant effects.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12579834",
                    "offsetInBeginSection": 655,
                    "offsetInEndSection": 894,
                    "text": "MT significantly reversed the locomotor activity increases, ameliorated learning and working memory deficit, and reduced the extent of CA1 hippocampal pyramidal cells injury after transient global cerebral ischemia in the Mongolian gerbil.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Is melatonin beneficial in the treatment of in cerebral ischemia-reperfusion injury:",
            "type": "yesno",
            "id": "65f0369bc4010b4d78000001",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/34920276",
                "http://www.ncbi.nlm.nih.gov/pubmed/17826015",
                "http://www.ncbi.nlm.nih.gov/pubmed/9989608",
                "http://www.ncbi.nlm.nih.gov/pubmed/11270862",
                "http://www.ncbi.nlm.nih.gov/pubmed/21662768",
                "http://www.ncbi.nlm.nih.gov/pubmed/12043962",
                "http://www.ncbi.nlm.nih.gov/pubmed/18175966",
                "http://www.ncbi.nlm.nih.gov/pubmed/25490393",
                "http://www.ncbi.nlm.nih.gov/pubmed/24463763",
                "http://www.ncbi.nlm.nih.gov/pubmed/35268098"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34920276",
                    "offsetInBeginSection": 1373,
                    "offsetInEndSection": 1503,
                    "text": "Dextr provides similar performance to manual extraction in terms of recall and precision and greatly reduces data extraction time.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34920276",
                    "offsetInBeginSection": 655,
                    "offsetInEndSection": 733,
                    "text": "Dextr was developed with Agile software methodology using a two-team approach.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17826015",
                    "offsetInBeginSection": 167,
                    "offsetInEndSection": 263,
                    "text": "Using chondroitin, dextran and dextrin as the base, self-dissolving needles (SDN) were prepared.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17826015",
                    "offsetInBeginSection": 782,
                    "offsetInEndSection": 930,
                    "text": "Almost the same PAs of LMWH were obtained with dextran and dextrin SDNs, 97.7% and 102.3%, though lower PA was obtained with chondroitin SDN, 81.5%.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17826015",
                    "offsetInBeginSection": 931,
                    "offsetInEndSection": 1050,
                    "text": "In vitro dissolution experiment showed that LMWH was released from dextran, dextrin and chondroitin SDNs within 10 min.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9989608",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 131,
                    "text": "Linear dextrins (alpha-1,4-D-glucopyranoside chains) are known to possess amphiphilic surfaces and solubilize lipophilic compounds.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9989608",
                    "offsetInBeginSection": 270,
                    "offsetInEndSection": 454,
                    "text": "Addition of decameric dextrin, or dextrin-10, in the renaturation buffer improves the refolding yield of human carbonic anhydrase from its guanidinium chloride-induced denatured state.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9989608",
                    "offsetInBeginSection": 515,
                    "offsetInEndSection": 760,
                    "text": "The ability of dextrin-10 to interact with cetyltrimethylammonium bromide and postpone its critical micellar concentration allows the use of dextrin-10 as a 'detergent stripping agent' in a novel artificial chaperoning process described earlier.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11270862",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 233,
                    "text": "The affinity interactions of Concanavalin A (Con A) with various saccharide oligomers (dextrins, dextrans, and selected N-linked glycans from various glycoproteins) have been investigated through a capillary electrophoresis approach.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21662768",
                    "offsetInBeginSection": 141,
                    "offsetInEndSection": 426,
                    "text": "We have employed size exclusion chromatography (SEC) with universal calibration to determine molecular weight averages, distributions, intrinsic viscosities, and structural parameters of Starburst dendrimers, dextrans, and the starch degradation polysaccharides known as maltodextrins.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is DEXTR",
            "type": "summary",
            "id": "65f37871c4010b4d7800000a",
            "ideal_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/36968986",
                "http://www.ncbi.nlm.nih.gov/pubmed/32044319",
                "http://www.ncbi.nlm.nih.gov/pubmed/36272109",
                "http://www.ncbi.nlm.nih.gov/pubmed/31781755",
                "http://www.ncbi.nlm.nih.gov/pubmed/31327403",
                "http://www.ncbi.nlm.nih.gov/pubmed/34042156",
                "http://www.ncbi.nlm.nih.gov/pubmed/34968730",
                "http://www.ncbi.nlm.nih.gov/pubmed/36898598",
                "http://www.ncbi.nlm.nih.gov/pubmed/33755884",
                "http://www.ncbi.nlm.nih.gov/pubmed/31701537"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36968986",
                    "offsetInBeginSection": 494,
                    "offsetInEndSection": 619,
                    "text": "Upadacitinib, an oral JAK1 inhibitor, has demonstrated efficacy in treating Crohn's disease during phase III clinical trials.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32044319",
                    "offsetInBeginSection": 2042,
                    "offsetInEndSection": 2186,
                    "text": "In a phase 2 trial of patients with CD, upadacitinib induced endoscopic remission in a significant proportion of patients compared with placebo.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36272109",
                    "offsetInBeginSection": 1525,
                    "offsetInEndSection": 1671,
                    "text": "In this real-world cohort of highly refractory CD patients, upadacitinib was effective in inducing remission and had an acceptable safety profile.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31781755",
                    "offsetInBeginSection": 709,
                    "offsetInEndSection": 797,
                    "text": "Upadacitinib also showed promising results in a phase II trial in moderate to severe CD.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31327403",
                    "offsetInBeginSection": 938,
                    "offsetInEndSection": 1086,
                    "text": "Following promising results for upadacitinib in its phase II trial, larger phase III trials were also initiated to corroborate the efficacy results.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34042156",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 110,
                    "text": "Janus kinase (JAK) inhibition shows promise for treatment of patients with moderate to severe Crohn's disease.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34968730",
                    "offsetInBeginSection": 1366,
                    "offsetInEndSection": 1525,
                    "text": "Sustained long-term benefit at 30 months and further endoscopic improvements to month 24 were observed in patients with Crohn's disease receiving upadacitinib.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34968730",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 176,
                    "text": "The long-term efficacy and safety of upadacitinib was evaluated in an open-label extension (OLE) of a phase II, double-blind, randomized trial of patients with Crohn's disease.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36898598",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 234,
                    "text": "Upadacitinib is a novel selective Janus kinase 1 inhibitor that has shown efficacy in the treatment of moderate to severe ulcerative colitis (UC) and Crohn's disease (CD), and has received Food and Drug Administration approval for UC.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33755884",
                    "offsetInBeginSection": 29,
                    "offsetInEndSection": 175,
                    "text": "positive efficacy results were obtained with the Janus kinase 1 inhibitor upadacitinib for adult patients with moderate to severe Crohn's disease.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Is Upadacitinib effective for Crohns Disease?",
            "type": "yesno",
            "id": "65d126471930410b1300002b",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/36837597",
                "http://www.ncbi.nlm.nih.gov/pubmed/31836032",
                "http://www.ncbi.nlm.nih.gov/pubmed/34776270",
                "http://www.ncbi.nlm.nih.gov/pubmed/8619274",
                "http://www.ncbi.nlm.nih.gov/pubmed/31513123",
                "http://www.ncbi.nlm.nih.gov/pubmed/28054978",
                "http://www.ncbi.nlm.nih.gov/pubmed/25697570",
                "http://www.ncbi.nlm.nih.gov/pubmed/28188676",
                "http://www.ncbi.nlm.nih.gov/pubmed/36443351",
                "http://www.ncbi.nlm.nih.gov/pubmed/12761018"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36837597",
                    "offsetInBeginSection": 739,
                    "offsetInEndSection": 794,
                    "text": "Hemopure is in clinical use in South Africa and Russia.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36837597",
                    "offsetInBeginSection": 795,
                    "offsetInEndSection": 919,
                    "text": "Oxyglobin, the sister product of Hemopure, has been approved for veterinary use in the European Union and the United States.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36837597",
                    "offsetInBeginSection": 920,
                    "offsetInEndSection": 1027,
                    "text": "HemO2life has recently been approved for organ preservation in organ transplantation in the European Union.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31836032",
                    "offsetInBeginSection": 261,
                    "offsetInEndSection": 429,
                    "text": "a higher overall incidence of mortality and myocardial infarction in those dosed with HBOCs in later stage clinical trials has prevented widespread regulatory approval.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34776270",
                    "offsetInBeginSection": 1301,
                    "offsetInEndSection": 1395,
                    "text": "Unfortunately, so far, no HBOC has been approved by FDA and EMA, except for compassionate use.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8619274",
                    "offsetInBeginSection": 496,
                    "offsetInEndSection": 663,
                    "text": "Although many of the metabolic and toxicologic consequences of HBOC infusion are not fully understood, an approved product will likely be available in the near future.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31513123",
                    "offsetInBeginSection": 1227,
                    "offsetInEndSection": 1380,
                    "text": "Several of these HBOCs have undergone rigorous preclinical and clinical evaluation, but have not yet received clinical approval in the USA for human use.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28054978",
                    "offsetInBeginSection": 189,
                    "offsetInEndSection": 416,
                    "text": "Human trials conducted so far by several manufactures in a variety of clinical indications, including trauma, and elective surgeries have failed and no product has gained the Food and Drug Administration approval for human use.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25697570",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 156,
                    "text": "Bovine-derived hemoglobin-based oxygen carriers (HBOCs) have been investigated for use in humans (HBOC-201) and approved for veterinary medicine (HBOC-301).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28188676",
                    "offsetInBeginSection": 640,
                    "offsetInEndSection": 795,
                    "text": "After approval by the U.S. Food and Drug Administration and the local institutional review board, 12 U of HBOC-201 were transfused over a period of 8 days.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Are Hemoglobin-Based Oxygen Carriers approved for human use?",
            "type": "yesno",
            "id": "65f84b5ec4010b4d78000048",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27293018",
                "http://www.ncbi.nlm.nih.gov/pubmed/31725541",
                "http://www.ncbi.nlm.nih.gov/pubmed/31797863",
                "http://www.ncbi.nlm.nih.gov/pubmed/16855369",
                "http://www.ncbi.nlm.nih.gov/pubmed/918595",
                "http://www.ncbi.nlm.nih.gov/pubmed/31542854",
                "http://www.ncbi.nlm.nih.gov/pubmed/15004306",
                "http://www.ncbi.nlm.nih.gov/pubmed/26430672",
                "http://www.ncbi.nlm.nih.gov/pubmed/29316703",
                "http://www.ncbi.nlm.nih.gov/pubmed/32233805"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27293018",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 206,
                    "text": "Congenital fibrinogen disorders are rare diseases affecting either the quantity (afibrinogenaemia and hypofibrinogenaemia) or the quality (dysfibrinogenaemia) or both (hypodysfibrinogenaemia) of fibrinogen.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31725541",
                    "offsetInBeginSection": 74,
                    "offsetInEndSection": 156,
                    "text": "Congenital fibrinogen disorders result from several mutations in FGA, FGB, or FGG.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31797863",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 224,
                    "text": "Congenital qualitative and quantitative fibrinogen disorders represent heterogeneous rare abnormalities caused by mutations in one of the 3 genes encoding individual fibrinogen polypeptide chains, located on chromosome 4q28.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16855369",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 396,
                    "text": "Inherited fibrinogen disorders can be classified into qualitative and quantitative anomalies: dysfibrinogenemia is characterised by normal circulating levels of fibrinogen with abnormal function; hypofibrinogenemia and afibrinogenemia are characterised by reduced or absent fibrinogen in circulation respectively,while hypodysfibrinogenemia is defined by reduced fibrinogen with reduced function.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/918595",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 94,
                    "text": "A family with congenital hypofibrinogenemia (fibrinogen levels of 60-90 mg%) has been studied.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/918595",
                    "offsetInBeginSection": 212,
                    "offsetInEndSection": 399,
                    "text": "Congenital hypofibrinogenemia appears to be a separate entity which can be distinguished from heterozygous individuals of congenital afibrinogenemia and from congenital dysfibrinogenemia.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31542854",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 146,
                    "text": "Congenital dysfibrinogenemia is characterized with undetectable or low fibrinogen level by Clauss assay complicated by bleeding and/or thrombosis.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15004306",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 88,
                    "text": "Congenital afibrinogenemia/hypofibrinogenemia is an extremely rare coagulation disorder.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26430672",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 184,
                    "text": "Congenital afibrinogenemia/hypofibrinogenemia is a rare inherited hematologic disorder in which a patient lacks or has insufficient level of fibrinogen, the blood coagulation factor I.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29316703",
                    "offsetInBeginSection": 267,
                    "offsetInEndSection": 654,
                    "text": "Since the identification of the first causative mutation for congenital afibrinogenemia, studies have elucidated the underlying molecular pathophysiology of numerous causative mutations leading to fibrinogen deficiency, developed cell-based and animal models to study human fibrinogen disorders, and further explored the clinical consequences of absent, low, or dysfunctional fibrinogen.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Please list the congenital fibrinogen disorders.",
            "type": "list",
            "id": "65f70a55c4010b4d7800001b",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/21987394",
                "http://www.ncbi.nlm.nih.gov/pubmed/24255592",
                "http://www.ncbi.nlm.nih.gov/pubmed/31883703",
                "http://www.ncbi.nlm.nih.gov/pubmed/35100444",
                "http://www.ncbi.nlm.nih.gov/pubmed/28754630",
                "http://www.ncbi.nlm.nih.gov/pubmed/33321511",
                "http://www.ncbi.nlm.nih.gov/pubmed/31831056",
                "http://www.ncbi.nlm.nih.gov/pubmed/32991803",
                "http://www.ncbi.nlm.nih.gov/pubmed/35401412",
                "http://www.ncbi.nlm.nih.gov/pubmed/24981190"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21987394",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 125,
                    "text": "Gantenerumab is a fully human anti-A monoclonal antibody in clinical development for the treatment of Alzheimer disease (AD).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24255592",
                    "offsetInBeginSection": 729,
                    "offsetInEndSection": 888,
                    "text": "Gantenerumab is an investigational fully human anti-amyloid beta monoclonal antibody with a high capacity to bind and remove beta-amyloid plaques in the brain.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31883703",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 229,
                    "text": "Gantenerumab, a fully human anti-amyloid- IgG1 monoclonal antibody that binds to aggregated forms of amyloid-, is being investigated as a potential disease-modifying treatment for early (prodromal to mild) Alzheimer disease (AD).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35100444",
                    "offsetInBeginSection": 246,
                    "offsetInEndSection": 490,
                    "text": "Gantenerumab, a fully human monoclonal antibody (mAb) that binds to aggregated amyloid-beta, was tested in two 24-month phase III studies (NCT01224106, NCT02051608) in participants with prodromal and mild Alzheimer's disease (AD), respectively.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28754630",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 66,
                    "text": "Gantenerumab is intended for the treatment of Alzheimer's disease.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33321511",
                    "offsetInBeginSection": 718,
                    "offsetInEndSection": 750,
                    "text": "Gantenerumab (targets A fibrils)",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31831056",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 96,
                    "text": "Gantenerumab reduces amyloid- plaques in patients with prodromal to moderate Alzheimer's disease",
                    "beginSection": "title",
                    "endSection": "title"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32991803",
                    "offsetInBeginSection": 420,
                    "offsetInEndSection": 473,
                    "text": "Gantenerumab and crenezumab are two anti-A antibodies",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35401412",
                    "offsetInBeginSection": 179,
                    "offsetInEndSection": 430,
                    "text": "Passive immunotherapy with aducanumab (Aduhelm), lecanemab, donanemab, and gantenerumab all lower CNS amyloid (A) burden but come with a significant risk of amyloid-related imaging abnormality (ARIA)-the most common side effect of this class of drugs.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24981190",
                    "offsetInBeginSection": 728,
                    "offsetInEndSection": 1022,
                    "text": "Two other monoclonal antibodies, gantenerumab, which preferentially binds to fibrillar A, and crenezumab, which preferentially binds to soluble, oligomeric and fibrillar A deposits, are being tested in secondary prevention trials in presymptomatic subjects with autosomal dominant AD mutations.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Gantenerumab was developed for treatment of which disease?",
            "type": "factoid",
            "id": "65cfa37c1930410b1300000d",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/36891369"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36891369",
                    "offsetInBeginSection": 1443,
                    "offsetInEndSection": 1519,
                    "text": "The PD method effectively treats low-birth-weight preterm neonates with AKI.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36891369",
                    "offsetInBeginSection": 1520,
                    "offsetInEndSection": 1649,
                    "text": "An adult Tenckhoff catheter was shortened by 2 cm and successfully used in the PD treatment of a low-birth-weight preterm infant.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Is peritoneal dialysis the best option for infants with kidney failure?",
            "type": "yesno",
            "id": "65f86e06c4010b4d7800005a",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/36552072",
                "http://www.ncbi.nlm.nih.gov/pubmed/32648856",
                "http://www.ncbi.nlm.nih.gov/pubmed/23473785",
                "http://www.ncbi.nlm.nih.gov/pubmed/25186006",
                "http://www.ncbi.nlm.nih.gov/pubmed/37564925",
                "http://www.ncbi.nlm.nih.gov/pubmed/35230651",
                "http://www.ncbi.nlm.nih.gov/pubmed/37979595",
                "http://www.ncbi.nlm.nih.gov/pubmed/33332483",
                "http://www.ncbi.nlm.nih.gov/pubmed/32799325",
                "http://www.ncbi.nlm.nih.gov/pubmed/34109839"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36552072",
                    "offsetInBeginSection": 461,
                    "offsetInEndSection": 587,
                    "text": "Zavegepant (BHV-3500, BMS-742413) belongs to the third generation of gepants characterized by different administration routes.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32648856",
                    "offsetInBeginSection": 704,
                    "offsetInEndSection": 804,
                    "text": "Ubrogepant can be administered as 50- and 100-mg tablets, with a maximum dose of 200 mg within 48 h.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23473785",
                    "offsetInBeginSection": 992,
                    "offsetInEndSection": 1146,
                    "text": "The same amount of reduction occurred after topical administration onto the paw, with resulting systemic plasma concentrations in the low nanomolar range.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25186006",
                    "offsetInBeginSection": 981,
                    "offsetInEndSection": 1147,
                    "text": "The same considerable amount of reduction occurred after topical administration onto the paw with resulting systemic plasma concentrations in the low nanomolar range.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37564925",
                    "offsetInBeginSection": 336,
                    "offsetInEndSection": 581,
                    "text": "Atogepant, the latest CGRP antagonist approved by the Food and Drug Administration (FDA) for prophylaxis of episodic migraine, works by non-competitively blocking CGRP receptors, thereby curtailing neurogenic inflammation and pain sensitization.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35230651",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 184,
                    "text": "Atogepant is the latest calcitonin gene-related peptide (CGRP) antagonist approved exclusively for prophylaxis of episodic migraine and is administered orally in doses of 10-60 mg/day.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37979595",
                    "offsetInBeginSection": 1528,
                    "offsetInEndSection": 1694,
                    "text": "During the double-blind treatment period, each participant was instructed to orally take two tablets of the study drug at the onset of each qualifying prodrome event.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33332483",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 206,
                    "text": "Rimegepant is an oral calcitonin gene-related peptide (CGRP) receptor antagonist developed with a novel quick-dissolve oral tablet formulation for the acute treatment of migraine by Biohaven Pharmaceuticals",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32799325",
                    "offsetInBeginSection": 2166,
                    "offsetInEndSection": 2290,
                    "text": "Rimegepant, when used as an oral acute treatment in patients receiving CGRP mAbs as preventive treatment, was well tolerated",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34109839",
                    "offsetInBeginSection": 354,
                    "offsetInEndSection": 502,
                    "text": "Ubrogepant is a calcitonin gene-related peptide receptor antagonist approved by the Food and Drug Administration for the acute treatment of migraine",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is the administration route of zavegepant?",
            "type": "factoid",
            "id": "65d1357c1930410b13000039",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/10992277",
                "http://www.ncbi.nlm.nih.gov/pubmed/11235821",
                "http://www.ncbi.nlm.nih.gov/pubmed/23830554",
                "http://www.ncbi.nlm.nih.gov/pubmed/12696209",
                "http://www.ncbi.nlm.nih.gov/pubmed/17076653",
                "http://www.ncbi.nlm.nih.gov/pubmed/15991946",
                "http://www.ncbi.nlm.nih.gov/pubmed/20518365",
                "http://www.ncbi.nlm.nih.gov/pubmed/10781782",
                "http://www.ncbi.nlm.nih.gov/pubmed/18031152",
                "http://www.ncbi.nlm.nih.gov/pubmed/14680461"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10992277",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 154,
                    "text": "Thalomid is the FDA-approved commercial formulation of thalidomide currently used in the US to treat erythema nodosum leprosum, a complication of leprosy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11235821",
                    "offsetInBeginSection": 236,
                    "offsetInEndSection": 405,
                    "text": "The US Food and Drug Administration (FDA) has approved Thalomid (thalidomide) capsules for the acute treatment of the cutaneous manifestations of moderate to severe ENL.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23830554",
                    "offsetInBeginSection": 906,
                    "offsetInEndSection": 969,
                    "text": "In May 2006, it was approved for the treating multiple myeloma.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12696209",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 80,
                    "text": "Thalidomide currently is used to treat relapsed and refractory multiple myeloma.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17076653",
                    "offsetInBeginSection": 563,
                    "offsetInEndSection": 867,
                    "text": "Novel FDA approved agents including thalidomide/thalomid, its immunomodulatory derivatives lenalidomide/Revlimid, and proteasome inhibitor bortezomib/Velcade are directed at molecular targets not only in MM cells but also in its BM milieu, and have already achieved promising results in clinical studies.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15991946",
                    "offsetInBeginSection": 496,
                    "offsetInEndSection": 662,
                    "text": "Recent clinical trials have shown thalidomide effective in graft-versus-host disease, Behcet's syndrome and aphthous ulcers and wasting associated with HIV infection.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20518365",
                    "offsetInBeginSection": 522,
                    "offsetInEndSection": 786,
                    "text": "The regimens for initial therapy that are based on level 1 evidence and consensus include bortezomib (Velcade)/dexamethasone, bortezomib/doxorubicin/dexamethasone, bortezomib/thalidomide (Thalomid)/dexamethasone, and lenalidomide (Revlimid)/low-dose dexamethasone.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10781782",
                    "offsetInBeginSection": 413,
                    "offsetInEndSection": 572,
                    "text": "Recently, the drug was approved for sale in the United States for the treatment of erythema nodosum leprosum, an inflammatory complication of Hansen's disease.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10781782",
                    "offsetInBeginSection": 573,
                    "offsetInEndSection": 855,
                    "text": "However, it has long been used successfully in several other dermatologic disorders, including aphthous stomatitis, Behcet's syndrome, chronic cutaneous systemic lupus erythematosus, and graft-versus-host disease, the apparent shared characteristic of which is immune dysregulation.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10781782",
                    "offsetInBeginSection": 856,
                    "offsetInEndSection": 1096,
                    "text": "Many recent studies have evaluated thalidomide in patients with human immunodeficiency virus (HIV) infection; the drug is efficacious against oral aphthous ulcers, HIV-associated wasting syndrome, HIV-related diarrhea, and Kaposi's sarcoma.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What are the current indications for thalidomide?",
            "type": "list",
            "id": "65f82218c4010b4d7800003e",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/15017037",
                "http://www.ncbi.nlm.nih.gov/pubmed/25229531",
                "http://www.ncbi.nlm.nih.gov/pubmed/9402711",
                "http://www.ncbi.nlm.nih.gov/pubmed/7744687"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15017037",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 216,
                    "text": "The presence of a heart-base tumor was diagnosed by ultrasound imaging in a 10-year-old, female, domestic shorthaired cat presenting with dyspnea and pleural effusion because of the presence of a modified transudate.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25229531",
                    "offsetInBeginSection": 1706,
                    "offsetInEndSection": 1835,
                    "text": "In dogs with VH, frequent serum biochemical analysis and ultrasonographic surveillance for early tumor detection are recommended.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9402711",
                    "offsetInBeginSection": 363,
                    "offsetInEndSection": 448,
                    "text": "There was good visual correlation of the lesion site by MRI and ultrasonography (US).",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7744687",
                    "offsetInBeginSection": 992,
                    "offsetInEndSection": 1124,
                    "text": "A large mass in the pituitary gland, suprasellar region, or both was easily identified on the magnetic resonance images of each dog.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7744687",
                    "offsetInBeginSection": 153,
                    "offsetInEndSection": 248,
                    "text": "Magnetic resonance imaging of the brain was performed in 13 dogs with PDH and neurologic signs.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Can Ultrasonography be used to detect tumors in dogs and cats?",
            "type": "yesno",
            "id": "65f5a3efc4010b4d78000017",
            "ideal_answer": "",
            "exact_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/25217396",
                "http://www.ncbi.nlm.nih.gov/pubmed/26880088"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25217396",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 196,
                    "text": "In sub-Saharan Africa, artemisinin-based combination therapy (ACT) and injectable artesunate are the first-line treatments for uncomplicated and severe Plasmodium falciparum malaria, respectively.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26880088",
                    "offsetInBeginSection": 2347,
                    "offsetInEndSection": 2674,
                    "text": "Uncomplicated P. falciparum malaria should be treated with an artemisinin combination therapy (Grade 1A). Artemether-lumefantrine (Riamet()) is the drug of choice (Grade 2C) and dihydroartemisinin-piperaquine (Eurartesim()) is an alternative. Quinine or atovaquone-proguanil (Malarone()) can be used if an ACT is not available.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "What is the first line treatment for severe Plasmodium falciparum malaria?",
            "type": "factoid",
            "id": "65f82058c4010b4d7800003d",
            "ideal_answer": "",
            "exact_answer": [
                []
            ]
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22303509",
                "http://www.ncbi.nlm.nih.gov/pubmed/22836185",
                "http://www.ncbi.nlm.nih.gov/pubmed/36891571",
                "http://www.ncbi.nlm.nih.gov/pubmed/31451057",
                "http://www.ncbi.nlm.nih.gov/pubmed/25349687",
                "http://www.ncbi.nlm.nih.gov/pubmed/16955152",
                "http://www.ncbi.nlm.nih.gov/pubmed/29201733",
                "http://www.ncbi.nlm.nih.gov/pubmed/6857456",
                "http://www.ncbi.nlm.nih.gov/pubmed/21477891",
                "http://www.ncbi.nlm.nih.gov/pubmed/31080246"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22303509",
                    "offsetInBeginSection": 241,
                    "offsetInEndSection": 361,
                    "text": "Imaging modalities and endoscopy may locate the lesion, but definitive diagnosis requires histopathological examination.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22836185",
                    "offsetInBeginSection": 480,
                    "offsetInEndSection": 616,
                    "text": "Brunner's gland proliferating lesions were categorized as Brunner's gland hamartoma or hyperplasia according to their tissue components.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36891571",
                    "offsetInBeginSection": 223,
                    "offsetInEndSection": 375,
                    "text": "Barium swallow may demonstrate the lesion, but endoscopic evaluation is the acceptable first line management unless a concern for underlying malignancy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31451057",
                    "offsetInBeginSection": 410,
                    "offsetInEndSection": 501,
                    "text": "The diagnosis is usually confirmed by imaging studies and upper gastrointestinal endoscopy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25349687",
                    "offsetInBeginSection": 400,
                    "offsetInEndSection": 561,
                    "text": "Endoscopic presentation can be nodular, polypoid or diffuse glandular proliferation with thickening of duodenal wall and hence can be misdiagnosed as malignancy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16955152",
                    "offsetInBeginSection": 167,
                    "offsetInEndSection": 264,
                    "text": "These hamartomas may be discovered incidentally during an upper gastrointestinal tract endoscopy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29201733",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 169,
                    "text": "Brunner gland hamartoma (brunneroma) is a rare benign tumor of the duodenum. It is usually asymptomatic and detected incidentally by endoscopy or other imaging modality.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16955152",
                    "offsetInBeginSection": 265,
                    "offsetInEndSection": 410,
                    "text": "Otherwise, they may be diagnosed in patients presenting with acute upper gastrointestinal bleeding, anemia or symptoms of intestinal obstruction.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/6857456",
                    "offsetInBeginSection": 564,
                    "offsetInEndSection": 647,
                    "text": "Confirmation of the diagnosis can be made upon biopsy of the duodenum at operation.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21477891",
                    "offsetInBeginSection": 486,
                    "offsetInEndSection": 590,
                    "text": "Both clinical and radiographic studies are nonspecific and often do not allow diagnosis of these tumors.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Brunner's gland hamartoma (BGH) is often asymptomatic and so how is it usually diagnosed?",
            "type": "summary",
            "id": "65f59db8c4010b4d78000014",
            "ideal_answer": ""
        },
        {
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/37902139",
                "http://www.ncbi.nlm.nih.gov/pubmed/37676096",
                "http://www.ncbi.nlm.nih.gov/pubmed/36931947",
                "http://www.ncbi.nlm.nih.gov/pubmed/38095822",
                "http://www.ncbi.nlm.nih.gov/pubmed/37419629",
                "http://www.ncbi.nlm.nih.gov/pubmed/37651294",
                "http://www.ncbi.nlm.nih.gov/pubmed/36586644",
                "http://www.ncbi.nlm.nih.gov/pubmed/38084203",
                "http://www.ncbi.nlm.nih.gov/pubmed/37927263",
                "http://www.ncbi.nlm.nih.gov/pubmed/37682322"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37902139",
                    "offsetInBeginSection": 997,
                    "offsetInEndSection": 1186,
                    "text": "The FDA approved lecanemab for Alzheimer's disease in January 2023 which acts as a novel disease-modifying anti-amyloid-beta (A) human monoclonal antibody and is administered intravenously.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37902139",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 176,
                    "text": "Lecanemab is the latest monoclonal antibody that targets beta-amyloid approved exclusively for treatment of Alzheimer's disease with mild cognitive impairment or mild dementia.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37676096",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 146,
                    "text": "On July 6, 2023, the U.S. Food and Drug Administration (FDA) approved lecanemab (Leqembi) for the treatment of Alzheimer's dementia (AD) patients.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36931947",
                    "offsetInBeginSection": 1329,
                    "offsetInEndSection": 1418,
                    "text": "Lecanemab has been recently approved by the FDA for the treatment of Alzheimer's disease.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38095822",
                    "offsetInBeginSection": 143,
                    "offsetInEndSection": 337,
                    "text": "Lecanemab, an anti-amyloid beta monoclonal antibody, is the first Alzheimer's disease drug targeting amyloid beta that has shown statistically significant cognitive benefits in phase III trials.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37419629",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 83,
                    "text": "Alzheimer's disease: Lecanemab gets full FDA approval and black box safety warning.",
                    "beginSection": "title",
                    "endSection": "title"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37651294",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 72,
                    "text": "Lecanemab (Leqembi) granted full approval for early Alzheimer's disease.",
                    "beginSection": "title",
                    "endSection": "title"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36586644",
                    "offsetInBeginSection": 414,
                    "offsetInEndSection": 690,
                    "text": "In June 2021, the FDA approved aducanumab, an anti-A monoclonal antibody for early AD based on its ability to reduce brain amyloid plaques, while two other amyloid-clearing antibodies (lecanemab and donanemab) have recently produced encouraging cognitive and clinical results.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38084203",
                    "offsetInBeginSection": 1585,
                    "offsetInEndSection": 1700,
                    "text": "In July 2023, the FDA granted lecanemab a full approval, and this therapeutic antibody will be marketed as Leqembi.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37927263",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 195,
                    "text": "The approval of lecanemab for the treatment of Alzheimer's disease (AD) by the Food and Drug Administration in the United States has sparked controversy over issues of safety, cost, and efficacy.",
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ],
            "body": "Is Lecanemab approved for Alzheimers Disease?",
            "type": "yesno",
            "id": "65ce88b71930410b13000001",
            "ideal_answer": "",
            "exact_answer": ""
        }
    ]
}